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ABSTRACT 
 
Polymorphisms in DNA repair genes and susceptibility to colorectal cancer 
 
Colorectal cancer represents a complex disease where susceptibility may be influenced 
by genetic polymorphisms in the DNA repair system and in the cell cycle control 
pathway. In the present study we investigated the role of nine single nucleotide 
polymorphisms in eight DNA repair genes on the risk of colorectal cancer in a hospital-
based case-control population (532 cases and 532 sex- and age-matched controls) from 
the Czech Republic. A similar investigation on the same cohort was done for three 
single nucleotide polymorphisms in cell cycle control genes (TP53 PIN3 and Arg72Pro, 
CCND1 G/A870). Data analysis showed that the variant homozygote for the 
Asn148Glu polymorphism in the APE1 gene was associated with a moderately 
increased risk of colorectal cancer, but the association was more pronounced for colon 
cancer (OR: 1.50, 95% CI 1.01-2.22; p=0.05). The data stratification according to age 
showed increased risk of colorectal cancer in the age group 64-86 years in individuals 
heterozygous (OR: 1.79, 95% CI 1.04-3.07; p=0.04) and homozygous (OR: 2.57, 95% 
CI 1.30-5.06; p=0.007) for the variant allele of the APE1 Asn148Glu polymorphism. 
Smokers homozygous for the variant allele of the hOGG1 Ser326Cys polymorphism 
showed increased risk of colorectal cancer compared to smokers carrying hOGG1 
326SerSer genotype (OR: 4.17, 95% CI 1.17-15.54; p=0.03). The analysis of binary 
genotype combinations showed increased colorectal cancer risk in individuals 
simultaneously homozygous for the variant alleles of APE1 Asn148Glu and hOGG1 
Ser326Cys in comparison to individuals carrying simultaneously the combination of 
homozygous genotypes for the wildtype alleles of the same genes (OR: 6.37, 95% CI 
1.40-29.02; p=0.02). Oldest patients exhibited also significantly increased risk of colon 
and rectal cancer due to genotype combinations of APE1 Asn148Glu and XPG 
Asn114His. No significant association emerged from cell cycle gene polymorphisms 
analyzed in this study (TP53 PIN3 and Arg72Pro, CCND1 G/A870). The analysis of 
binary genotype combinations showed increased colon cancer risk in individuals 
simultaneously homozygous for the variant alleles of the TP53 polymorphisms (PIN3 
and Arg72Pro). Considering the subtle effect of the DNA repair polymorphisms on the 
risk of colorectal cancer, exploration of gene-gene and gene-environmental interactions 
requires large sample size for sufficient statistical power. 
Keywords: Colorectal cancer, individual susceptibility, DNA repair, single-nucleotide 
polymorphisms, case-control study 
RIASSUNTO 
 
Il cancro colon-rettale rappresenta un tipo di malattia molto complessa la cui 
suscettibilità può essere influenzata dai polimorfismi a geni del sistema di riparazione 
del DNA o a geni implicati nel controllo del ciclo cellulare. Nel presente studio è stato 
analizzato il possibile ruolo di nove polimorfismi a singolo nucleotide in otto geni 
facenti parte del sistema di riparazione del DNA nell’incremento del rischio di cancro 
colon-rettale in una popolazione di casi e controlli proveniente dalla Repubblica Ceca 
(532 casi e 532 controlli appaiati per sesso ed età). Una simile analisi sulla stessa 
popolazione è stata eseguita per quanto riguarda l’effetto di tre polimorfismi a singolo 
nucleotide di due geni implicati nel controllo del ciclo cellulare (TP53 PIN3 and 
Arg72Pro, CCND1 G/A870) nella suscettibilità al cancro colon-rettale. 
Dall’analisi dei risultati è emerso che il genotipo omozigote variante per il 
polimorfismo Asn148Glu al gene APE1 è risultato associato con un moderato 
incremento del rischio per il tumore al colon-retto, l’associazione risultava più 
pronunciata per il rischio del solo tumore al colon (OR: 1.50, 95% CI 1.01-2.22; 
p=0.05). Dall’analisi stratificata in accordo con l’età alla diagnosi è emerso un 
incremento statisticamente significativo nel rischio di manifestazione di un cancro 
colon-rettale nel gruppo di individui di età compresa tra 64 e 86 anni e portanti il 
genotipo eterozigote (OR: 1.79, 95% CI 1.04-3.07; p=0.04) ed omozigote (OR: 2.57, 
95% CI 1.30-5.06; p=0.007) per l’allele variante del polimorfismo di APE1 Asn148Glu. 
Fumatori che presentavano il genotipo omozigote variante per il polimorfismo 
Ser326Cys del gene hOGG1 presentavano un incremento significativo nel rischio per 
questo tipo di tumore se confrontati con la popolazione di fumatori di controllo (OR: 
4.17, 95% CI 1.17-15.54; p=0.03).  
Dall’analisi delle combinazioni binarie di polimorfismi a geni facenti parte dello stesso 
pathway di riparazione del DNA è emerso un incremento significativo nel rischio di 
cancro colon-rettale per gli individui portatori simultaneamente dei genotipi omozigoti 
per gli alleli varianti dei polimorfismi APE1 Asn148Glu e hOGG1 Ser326Cys (OR: 
6.37, 95% CI 1.40-29.02; p=0.02). La sottopopolazione di individui più anziani (64-86 
anni) presentava, inoltre, un incremento nel rischio di cancro al colon e al retto quando 
presenti particolari combinazioni di genotipi per i polimorfismi APE1 Asn148Glu e 
XPG Asn114His. Nessuno dei polimorfismi ai geni del ciclo cellulare analizzati (TP53 
PIN3 and Arg72Pro, CCND1 G/A870) è stato associato con un incremento significativo 
del rischio di tumore colon-retto. Dall’analisi delle combinazioni binarie è stato 
osservato, tuttavia, un incremento significativo nel rischio di cancro al colon per gli 
individui portatori simultaneamente dei genotipi omozigoti per gli alleli varianti dei 
polimorfismi al gene TP53 (PIN3 and Arg72Pro). I risultati emersi dal presente studio 
suggeriscono che ci possa essere un sottile effetto modulatore dei polimorfismi dei geni 
della riparazione del DNA nella suscettibilità al cancro colon-rettale, soprattutto nel 
caso di particolari combinazioni di genotipi “sfavorevoli”. L’analisi di tali interazioni 
gene-gene e di eventuali interazioni dei geni con l’ambiente richiedono, però, 
popolazioni di studio più ampie per avere un sufficiente potere statistico. 
1. Introduction 
 
 
1.1 Colorectal cancer: importance and causes 
 
Colorectal carcinoma (CRC) is one of the most frequent causes of cancer death in 
industrialized countries, with a yearly incidence of about 50 new cases for every 
100.000 people in the population, and an individual lifetime risk approaching 5% 
(Boyle and Ferlay 2005, Jemal et al., 2006). The well-defined sequence of events in 
this tumour development, from aberrant crypt proliferation or hyperplasia to benign 
adenomas, then to carcinoma in situ and finally to metastatic carcinoma, attests to 
the step like progression of this cancer, which often occurs over many years (de la 
Chapelle, 2004). These distinctive morphological stages can be visualized by 
colonoscopy, enabling the removal of pre-malignant lesions and of early malignant 
tumors.  
CRC is traditionally divided into sporadic and familial (hereditary) forms, the 
proportion of familial CRC accounting for 20–25% of the total number of cases. The 
majority of CRC cases is sporadic or shows a pattern of familial aggregation, not 
easily fitting into models of Mendelian inheritance (de la Chapelle, 2004). Genetics 
plays a key role in the susceptibility, initiation and progression of CRC. Genetic 
syndromes predisposing to CRC include the polyposis syndromes (familial 
adenomatous polyposis (FAP), Peutz-Jeghers syndrome, and Juvenile polyposis) 
and hereditary non-polyposis colon cancer (HNPCC). However, these syndromes 
account for about 3% of all cases (Aaltonen et al., 1998, Samowitz et al., 2001) and 
are not responsible for the 2-fold increased risk in first-degree relatives of sporadic 
CRC patients. This increased risk in relatives suggests a possible mild genetic 
predisposition, such as, for instance, an involvement of low-penetrance genes or 
gene combinations. 
CRC is a complex disease, whose development is determined by different 
combinations of genetic and environmental causes. These include on one hand 
dietary and lifestyle habits and on the other hand genetic factors (Potter, 1999). Rare 
and highly penetrant mutations in cancer genes may act with environmental 
influence. As the majority of CRC cases are sporadic, environmental factors are 
 1
thought to have an important role in the development of this disease. Increasingly 
large epidemiological studies have contributed to highlight the role of diet and 
lifestyle in humans over the last 40 years: they have established a positive 
correlation between CRC risk and the intake of fat, red meat and alcohol, as well as 
smoking (Giovannucci, 2001, Norat and Riboli, 2001). On the contrary, an inverse 
correlation has been observed between CRC risk and intake of vegetables and fibres 
(Terry et al., 2001, Young et al., 2005). Other non-dietary environmental life-style 
factors with protective effects include: higher levels of physical activity, hormone 
replacement therapy (HRT) in postmenopausal females, and the regular use of non-
steroidal anti-inflammatory drugs (NSAIDs), such as aspirin (Greenberg et al, 1993, 
Giacosa et al., 1999). Many associations are still controversial, and in most cases 
little is known about the mechanisms that contribute to enhance/diminish cancer 
risk. The difficulties in understanding main risk factors in CRC onset can be due to 
the fact that there are not single events predisposing to cancer development, but a 
sort of tight interaction between genetic and environmental factors with different 
degrees of involvement of either. Various situations may occur: tumorigenesis can 
require a close interaction between genetic risk factors and specific exposure to 
initiate the procedure or, genetic and environmental factors can complement and/or 
enhance each other, or, in an opposite situation, one of the two components can be 
protective in respect to the other. It is believed that a chronic disease, such as 
sporadic CRC, more likely involves multiple genes with moderate effects (low 
penetrance type) and progress materializes due to aggressive gene-environment 
interactions (Ahmed, 2006). Thus, it is reasonable to expect also the presence of 
several low-penetrance genes, which may influence the effects of both genetic and 
environmental factors contributing to CRC susceptibility. These genes, although 
none of them has been clearly identified, may account for either cases of hereditary 
CRC, or mainly for cases of CRC that are classified as ‘sporadic’. Therefore, the 
distinction between ‘sporadic’ and ‘familial’ cases and between ‘genetic’ and 
‘environmental’ predisposing factors has become blurred, and might be better 
thought of as a continuum of risks contributing to CRC development (de la 
Chapelle, 2004). 
Primary and secondary prevention of CRC are very important: this is proven by the 
fact that although its prevalence has been steadily increasing over the last century, 
mortality rates have declined, as a consequence of both improved treatment and 
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efficient screening and surveillance (Jemal et al., 2006). Occult fecal blood testing is 
a widely used and relatively simple option, but its sensitivity and specificity are still 
far from satisfactory. Endoscopy is certainly a more efficient tool, but its invasive 
nature and associated risks hamper its application on a population-wide scale. 
Interventions associated with changes in dietary and lifestyle habits (primarily 
smoking and alcohol consumption) and environmental exposure are, of course, 
strategies that would also reduce the risk of CRC, but again, it is extremely difficult 
to operate on population-wide scale (Heavey et al., 2004). The ultimate goal of an 
extensive primary prevention would be a stratification of the population into CRC 
risk categories, which could allow targeted prevention, with the adoption of 
measures tailored according to individual risk levels. In order to achieve this goal, 
accurate knowledge on the etiology and pathogenesis of the disease is needed, as 
well as the relationships between an individuals` genetic background and the 
relevance of environmental factors (Baglioni and Genuardi, 2004). 
 
Colorectal cancer incidence in the Czech Republic: a negative record  
High incidence of CRC is concentrated in developed countries and there is a high 
mortality in the countries of Central and Eastern Europe. The underlying cause may 
be mainly insufficient prevention, unhealthy nutrition and bad life style, which can 
lead to higher frequency of the disease. CRC represents a serious health problem in 
particular in the Czech Republic, as the incidence for colon cancer ranks the third 
highest worldwide and the incidence of rectal cancer is the highest (Boyle and 
Langman, 2000, Janout and Kollarova, 2001, Parkin et al, 2005) (Figure 1 and 2). 
Malignant neoplasms have been registered in the Czech Republic since the late 
1950s, with the establishment of the National Cancer Registry of the Czech 
Republic (NCR) in 1976 (Cancer Incidence 2002 in the Czech Republic). Compared 
to other European countries, the Czech Republic presents a rather long and historical 
recording of cancer incidence. Colorectal malignant neoplasms are the second most 
frequent kind of cancer recorded in this country (last updated calculation 
31/12/2002). In 2002 there were 8022 reported cases, accounting for 12.3 % of all 
reported malignant neoplasms and carcinoma in situ. It affects both men and 
women, with somewhat higher incidence among the former (58.7 %). The gravity of 
this illness is confirmed by the fact that it ranks second both in incidence and in 
mortality (15.6 % of all deaths from cancer were connected with colorectal cancer). 
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Mortality of men from CRC is the highest worldwide. Mortality among women is 
only exceeded by Hungarian women. (Cancer Incidence 2002 in the Czech 
Republic). 
 
 
Figure 1 Age standardized (European) incidence rates, bowel cancer in EU countries, by sex, 2002 
estimates (Modified from IARC, GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence 
Worldwide (2002 estimates) 2005) 
 
Figure 2 Worldwide incidence of colorectal in males (Modified from Parkin et al, 2005) 
(Age standardised (world) rate per 100,000) 
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1.2 Importance of low-penetrance genes in CRC 
 
The identification of polymorphisms (the occurrence in the same population of 
multiple discrete allelic states of which at least two have high frequency, 
conventionally of 1% or more) in genes associated with carcinogen metabolism has 
stimulated several years ago the development of a hypotheses to explain the high 
degree of individual variability in cancer susceptibility that has been observed by 
epidemiologists (Vineis, 2004). The successful sequencing of the human genome 
has provided the identification of a large number of low-penetrance alleles and 
simultaneously molecular epidemiology has acquired the technological devices to 
design large-scale case-control association studies. However, many results from 
epidemiologic studies have been inconsistent, particularly because of 1) low 
statistical power for detecting a moderate effect, mainly due to small size of 
analyzed cohorts, 2) false-positive results, 3) heterogeneity across study populations, 
like ethnic differences in genetic background, 4) failure to consider effect modifiers 
such as environmental exposures, and 5) publication bias versus negative results 
(Wacholder et al., 2004). In addition, it is becoming clear that a major need in 
association studies is to identify biologically plausible functional reflections of 
many polymorphisms, as well as gene-gene and gene-environment interactions 
(Rebbeck et al., 2004). Interaction between dietary and other environmental factors 
and single-nucleotide polymorphisms (SNPs) in specific genes have been proposed 
to explain much of the inter-individual variations in cancer, and provide a 
mechanistic explanation for the lack of evidence of effect of some promising dietary 
factors in chemoprevention studies (Figure 3). 
The number of candidate genes in the case of CRC, i.e. genes that may influence the 
development of this type cancer, is extremely wide and many of them possess 
known high-frequency low-penetrance alleles (de La Chapelle, 2004). Genes 
implicated in metabolic pathways, in methylation, or in DNA repair, as well as 
oncogenes, tumor suppressor genes, genes modifying the colonic microenvironment, 
and genes involved in the immune response have been so far addressed in this 
respect as a candidate gene for CRC susceptibility (de Jong, 2002). Low-penetrance 
variants in high-penetrance genes (e.g., APC, MLH1, or MSH2) might also be 
important in sporadic and familial CRC. The APC Ile1307Lys polymorphism, for 
instance, represents the strongest case for the existence of CRC susceptibility alleles 
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conferring moderate risk increase. Although the functional properties of the APC 
protein are not modified by the presence of a lysine instead of an isoleucine, the 
underlying DNA sequence change, i.e. a substitution of a thymine for an adenine, 
determines the appearance of a short hypermutable poly-A repeat (Laken et al., 
1997). This increases the likelihood that a first somatic hit, represented by APC 
sequence frameshifts, will occur in somatic cells, thus determining a higher CRC 
risk. Several studies have reported that the high frequency of APC 1307Lys variant 
among individuals of Ashkenazi descent corresponds to an approximately two-fold 
lifetime risk of CRC compared to the general population (Gryfe et al., 1999, Rozen 
et al., 2002). 
The following part provides a brief overview of the main pathways in which genetic 
polymorphisms have been investigated in association with CRC risk.  
 
Gene
Caretaker Genes
•DNA Repair
•Carcinogen Metabolism
Gatekeeper Genes
•Cell Cycle Control
•Programmed Cell Death
Landscaper Genes
•Signal transduction
pathways
Macro Environment
•Chemicals
•Viruses
•Radiation
•Physical Agents
Micro Environment
•Oxyradicalsicals
•Hormones
•Growth Factors
Cancer
Interindividual
variation
Environment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 The possible interactions of genes with external/internal environmental factors modulate 
individual genetic susceptibility in sporadic CRC risk (modified from Ahmed, 2006).  
 
• Metabolism  
Xenobiotic in the body are activated or inactivated by metabolic enzymes (XMEs). 
Most XMEs gene have several genetic polymorphisms, which can affect their 
activities, and modify metabolic pathways. As proposed by Vainio et al (2002), the 
general host metabolic status can be a crucial factor that enhances or reduces cancer 
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progression. The results of a meta-analysis on association studies about XME 
polymorphisms and risk of CRC have showed that GSTT1 deletion is a risk factor 
for this kind of cancer together with NAT2-rapid acetylator phenotype and genotype 
and NAT2-rapid acetylator phenotype (Chen et al. 2005),. However, the authors 
concluded that since CRC is also associated with several environmental and dietary 
risk factors that should be always carefully considered in the relationship with 
genetic polymorphisms of metabolic enzymes.  
• Methylation  
Imbalanced DNA methylation, characterized by genomic hypomethylation (Goelz et 
al., 1985) and methylation of usually unmethylated CpG sites (Issa et al., 1994), is 
observed consistently in CRC. The 5,10 MTHFR enzyme plays the most important 
role in DNA methylation and synthesis (Powers, 2005). The most common 
polymorphisms in the MTHFR gene, Cys677Thr and Ala1298Cys, have been 
frequently analyzed in association with CRC and adenoma risk. Recently, based on 
the evaluation of 16 studies, a decreased risk has been observed for carriers of the 
677ThrThr genotype in the majority of the cases, independently from the low/high 
folate status. On the contrary inconclusive results emerged for the Ala1298Cys 
polymorphism, probably due to the limited number of data available so far (Kono 
and Chen, 2005).  
• Immune response genes 
Chronic inflammation has a relevant impact on crucial cellular processes such as 
proliferation, adhesion, apoptosis, angiogenesis, and transformation processes and 
has been implicated as one of the most important factors in the development of 
CRC. At the cellular level, the colon epithelium is exposed to a variety of toxic and 
pathogenic agents. Alterations of intestinal microflora may result in a change in 
immune response, including the induction of inflammation (Macdonald and 
Monteleone, 2005). The release of proinflammatory cytokines by infiltrating 
lymphocytes usually accompanies these processes, leading to the generation of 
reactive oxygen species and other genotoxic compounds in the epithelial 
environment. Several studies indicate that local immunoregulation and associated 
cytokines have a putative role in the development of cancer, especially for 
gastrointestinal tumors. Genetic polymorphisms of the related cytokine encoding 
genes directly influence inter-individual variation in the magnitude of response, and 
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this may clearly contribute to the individual ultimate clinical outcome (MacArthur et 
al., 2004). A striking example is provided by Helicobacter pylori–induced gastritis, 
in which particular alleles for these proinflammatory genes have been associated 
with an increased risk of gastric cancer (El-Omar et al., 2001). Several studies have 
investigated the possible associations between cytokines and CRC risk. Common 
variants of proinflammatory cytokines IL6, IL8, and IL10 have been associated with 
CRC risk (Landi et al., 2003, MacArthur et al. 2004, Viet et al., 2005). 
Interesting associations have also been reported for polymorphisms of other genes 
involved in inflammatory processes, like the prostaglandin H synthase (PTGS, also 
known as cyclooxygenase, catalyzing the conversion of arachidonic acid to 
prostaglandin precursors, and mediating a wide range of cell functions) and the 
peroxisome proliferator-activated receptor g (PPARg, a nuclear receptor that 
functions as a transcriptional regulator of metabolism). Allelic variants of PTGS2 
have been investigated with colorectal carcinomas and adenomas with conflicting 
outcomes in several studies (Lin et al., 2002, Ali et al., 2005), while a variant within 
the PTGS2 promoter region has been recently associated with colorectal adenoma 
among non-NSAID users (Ulrich et al., 2005). Also a common PPARg SNP in exon 
12, which leads to a nonsynonymous amino acid substitution, has been associated 
with CRC and colorectal adenoma risk (Landi et al., 2003, Gong et al., 2005). 
• Oncogenes and Tumor Suppressor genes 
The proto-oncogene HRAS1 encodes a protein involved in mitogenic signal 
transduction and differentiation, and the HRAS1 gene is highly polymorphic in the 
human population (Heim and Mitelman, 1987). The few available studies on the 
HRAS1 polymorphisms are heterogeneous; the number of different HRAS1 alleles 
range from 5 up to 20 according to different authors, and this situation makes it 
difficult to compare data obtained in different laboratories. However, in most studies 
there are four common alleles, whereas the rest of the variant alleles are rare. The 
variant HRAS1 alleles have been associated with a moderately increased CRC risk 
(Klingel et al., 1991, Gosse-Brun et al., 1998). 
Gene polymorphisms were also shown to affect: (a) growth control at the cellular 
level (cell proliferation, differentiation and death); (b) factors involved in tumor 
invasion and metastasis (extracellular matrix remodeling, angiogenesis and cell 
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adhesion); (c) action of hormones and vitamins on growing tumors; and (d) outcome 
of cancer therapy (pharmacogenetics) (Ahmed, 2006). 
Other processes in which genetic polymorphisms have been investigated in 
association with CRC risk are DNA repair and Cell-cycle control. The following 
section provides an overview on these two important pathways. 
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1.3 DNA repair  
 
The genome is continuously attacked by endogenous and exogenous mutagens. 
Unrepaired damage can ultimately result in apoptosis or may lead to unregulated 
cell growth and cancer. When the DNA damage is recognized by cell machinery, 
several responses may occur to prevent replication in the presence of genetic errors: 
checkpoints can be activated to arrest the cell cycle, transcription can be up-
regulated to compensate for the damage, or the cell can undergo apoptosis. 
Alternatively, the damage can be repaired at the DNA level enabling the cell to 
replicate. The individual DNA repair capacity is a complex system of defenses 
designed to protect the integrity of the genome. DNA repair is thus of primary 
importance in the general and specialized functions of cells, as well as in the 
prevention of carcinogenesis (Hoeijmakers, 2001, Kaina, 2003).  
DNA repair is commonly divided into five major pathways (direct damage reversal, 
base excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR), and double strand break repair (DSB repair)), each dealing with specific 
types of lesions (Gillet and Scharer 2006). 
 
Nucleotide Excision Repair (NER) 
NER is a particularly intriguing repair pathway due to its extraordinarily wide 
substrate specificity. It has the ability to recognize and repair a large number of 
structurally unrelated lesions, such as DNA damage induced by UV radiation from 
sunlight and numerous bulky DNA adducts induced by environmental xenobiotics 
or by cytotoxic drugs used in chemotherapy. Defects in NER are related to various 
pathologies: a) Xeroderma Pigmentosum (XP), a recessive genetic disease that 
induces in XP patients an extreme sensitivity to sunlight and a more than 1000-fold 
increased risk to develop skin cancer; b) Cockayne syndrome (CS) is characterized 
by UV sensitivity but also by additional symptoms such as short stature, severe 
neurological abnormalities caused by dysmyelination, bird-like faces, tooth decay, 
and cataracts. CS patients have a mean life expectancy of 12.5 years but in contrast 
to XP do not show a clear predisposition to skin cancer; c) Trichothiodystrophy 
(TTD), (literally: “sulfur-deficient brittle hair”), in addition to the symptoms shared 
with CS patients, TTD patients show characteristic sulfur-deficient, brittle hair and 
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scaling of the skin. This genetic disorder is now known to correlate with mutations 
in genes involved in NER (such as XPB, XPD, and TTDA genes) (Gillet and Scharer 
2006) 
NER operates through a “cut-and-patch” mechanism in 4 stages: 
1. DNA damage recognition by a protein complex including XPC; 
2. Unwinding of DNA helix by TFIIH complex which includes XPD; 
3. Excision and removement of a short stretch of DNA (24- to 32-nucleotides 
long) containing the damaged base by several molecules and complexes that 
includes XPF-ERCC1; 
4. The original genetic sequence is then restored using the non-damaged strand 
of the DNA double helix as a template for repair synthesis. 
In eukaryotic cells the process of NER requires more than 30 proteins (Van Hoffen 
et al., 2003). 
Two distinct subpathways have been discerned: global genome NER (GG-NER), 
which can detect and remove lesions throughout the genome, and transcription 
coupled NER (TC-NER), which ensures faster repair of many lesions when located 
on the transcribed strand of actively transcribed genes (Figure 4). 
• Global Genome NER (GG-NER) 
GG-NER is considered to be transcription-independent, removing lesions from non-
transcribed regions of genome in addition to non-transcribed strands of transcribed 
regions. At least two proteins have been identified and implicated in the lesion 
recognition step of NER: the XPC gene product in complex with HR23B and the 
DNA damage binding protein (DDB) complex consisting of a heterodimer of the 
XPE, protein p48 and p127. The XPC-HR23B complex has strong specific affinity 
for damaged DNA, directly binding to the lesion. It is essential for the formation of 
the incision complex. DDB is required for repair of moderately helix distorting 
DNA lesions. The damage recognition by the XPC-HR23B complex is greatly 
facilitated by the DDB complex (Van Hoffen et al. 2003; Gillet and Scharer 2006). 
• Transcription Coupled NER (TC-NER) 
The preferential repair of UV-induced damage in transcribed strands of active genes 
is known as TC-NER. Impairment of the ability for TC-NER results in the onset of 
an autosomal recessive CS disease, characterized by hypersensitivity to UV light. 
TC-NER depends on active RNA polymeraseI and II driven transcription and is 
specifically targeted to DNA lesions in the transcribed strand of an active gene. 
 11
DNA lesions that induce poor helix distortion can block the movement of elongation 
by RNA Pol II. This can lead RNA Pol II to stalling and subsequent triggering of 
repair mechanisms by TC-NER resulting in an accelerated repair of DNA lesion in 
the transcribed strand compared to repair of non-expressed DNA. CSA and CSB 
gene products recognize the damage in that case. CSB gene encodes for a 168 kDa 
protein with particular importance, since its mutations may abolish completely TC-
NER systém, causing the block of RNA polymerase (Van Hoffen et al. 2003; Gillet 
and Scharer 2006). 
 
The sequential steps following the initial recognition of DNA lesions by GG-NER 
and TC-NER are similar. 
 
 
 
Figure 4 NER in mammalian cells. The damage recognition step is different for GGR and TCR. 
Once the damage is recognized, the processing of the damage requires the same steps and proteins in 
both subpathways (Modified from Van hoffen et al, 2003). 
 
XPA, RPA, XPC-HR23B, and DDB were found to exhibit an affinity for damaged 
DNA and were thus proposed to be involved in the damage recognition step of NER 
(Figure 4). XPB and XPD were identified as two ATP dependent helicases 
(unwinding 3´-5´and 5´-3 ´duplex DNA, respectively), subunits of the transcription 
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factor IIH (TFIIH) complex involved in basal transcription. This suggested a novel 
function for the whole TFIIH complex during the NER process, in generating an 
open DNA structure around the lesion. ERCC1- XPF and XPG were found to be 
structure-specific endonucleases that incised DNA at single-stranded/double-
stranded junctions with a specific polarity. ERCC1-XPF and XPG were thus 
proposed as the two nucleases performing the dual incision on the damaged strand, 
respectively, 5´- and 3´- to the lesion. PCNA (proliferating cell nuclear antigen) has 
also been shown to be required for NER in vitro, i.e. for the DNA resynthesis step, 
suggesting that DNA polymerase δ or ε is involved in NER, most probably in the last 
steps before completing repair process (Gillet and Scharer, 2006). 
 
Base Excision Repair (BER) 
BER is fundamentally important in handling diverse lesions produced as a result of 
the intrinsic instability of DNA or by various endogenous and exogenous reactive 
species. The initial step of BER involves enzymatic activities that process the N-
glycosylic bonds linking the target bases and their deoxyribose sugars. DNA 
glycosylases acting on other diverse lesions (alkylated, oxidized, or photodamaged 
bases, as well as some mispaired bases) have been characterized for their 
biochemical properties and biological roles in BER. Mammalian cells contain at 
least 10 distinct glycosylase activities. For example, the product of the OGG1 gene 
catalyzes the excision of a modified base, 8-oxoguanine, from DNA that has been 
damaged by exposure to reactive oxygen species; reduced ability to excise 8-
oxoguanine may lead to an accumulation of oxidation-induced mutations (Goode et 
al, 2002; Ide and Kotera, 2004). 
The initial product of a DNA glycosylase is an abasic, apurinic⁄apyrimidinic (AP), 
site in DNA, which is the central intermediate during BER (Sung and Demple, 
2006). 
A simplified version of BER for AP sites can be described as follows: 1) enzymatic 
incision of the AP site; 2) excision of the cleaved AP site at the single-strand break; 
3) repair DNA synthesis; 4) ligation of the nick in DNA. In mammalian cells, the 
major AP endonuclease, APE1, hydrolyzes the 5´ phosphodiester bond of the AP 
site to generate a DNA repair intermediate that contains a single strand break with 
3´-hydroxyl and 5´-deoxyribose- 5-phosphate (5´-dRP) termini. Further repair is 
achieved through at least two distinct BER subpathways that involve different 
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subsets of enzymes, and which result in the replacement of one nucleotide (short-
patch BER), or two or more nucleotides (long-patch BER) (Figure 5). 
 
 
Figure 5 BER in mammalian cells. BER acts on small lesions and involves release of the damaged 
base and removal of up to a few neighboring nucleotides. Two distinct BER subpathways are 
described (Modified from Sung and Demple, 2006). 
 
The resulting 3´-OH terminus is extended by Pol β and at the same time 5´-dRP 
terminal is removed by AP lyase activity associated with Pol β , and finally the nick 
is sealed by DNA ligase III/XRCC1. The net reaction in this BER process is the 
replacement of a single nucleotide unit, and is called short-patch BER. In the other 
subpathway of BER, long-patch BER, Pol δ or Pol ε synthesizes several nucleotides 
by displacing the downstream strand containing 5´-dRP. The resulting flap structure 
bearing 5´-dRP is incised by flap endonuclease (FEN1), and the nick is sealed by 
DNA ligase I. PCNA interacts with Pol δ/ε, FEN1, and DNA ligase I throughout the 
process, supporting their functions. The long patch BER pathway appears to have a 
crucial role in processing oxidized or reduced AP sites that are resistant to the AP 
lyase activity of Pol β (Ide and Kotera, 2004; Sung and Demple, 2006). 
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Double-strand breaks repair (DSB Repair) 
The DSB is perhaps the most dangerous of the various types of DNA damage that 
can occur within the mammalian cell. DSBs are induced by ionizing radiation (X-
rays or γ-rays) as well as by radiomimetic drugs used for chemotherapy. Moreover, 
the by products of cellular metabolism (reactive oxygen species or ROS) can also 
induce these breaks. DSB are also generated when a replication fork passes through 
a template with a nick. Ultimate result is the generation of free oxygen radicals 
which can break the phosphodiester bonds in the DNA backbone. Two such breaks 
on opposite strands of DNA, located closely to each other, result in a DSB.  
DNA DSB, as opposed to single-strand nicks or base modifications, can easily lead 
to gross chromosomal aberrations if not rejoined quickly. Even if repaired quickly, 
the repair process may be error-prone, and may eventually be detrimental to the 
organism. Mammalian cells, therefore, have mechanisms for quickly transmitting 
the damage signal to the cell cycle arrest or apoptotic machineries and mechanisms 
for DNA repair. Cell cycle arrest is necessary for providing the cell enough time for 
repair and, in some cases, it may be more prudent for the cell to undergo apoptosis 
when faced with excessive or unrepairable DNA damage. Both above processes 
represent effective barriers to carcinogenesis. The other important barrier to 
genomic instability and carcinogenesis is DSB repair (Burma et al, 2006) 
Repair of DSB is intrinsically more difficult than other types of DNA damage 
because no undamaged template is available (Khanna and Jackson, 2001). At least 
two pathways of DSB are arbitrarily recognized: the homologous recombination 
(HR) pathway and the non-homologous end-joining repair (NHEJ) pathway. HR is 
operative only in the S/G2 phases of the cell cycle when a sister chromatid is 
available. NHEJ, which simply pieces together the broken DNA ends, can function 
in all phases of the cell cycle and is the predominant repair pathway in mammalian 
cells. 
? Homologous recombination (HR) pathway  
HR is generally an error-free pathway of homology-directed repair. A DSB is 
accurately repaired by using the undamaged sister chromatid as a template for the 
repair of the broken sister chromatid (Figure 6). Homologous recombination in 
eukaryotes is carried out by the RAD52 epistasis group of proteins. In human cells, 
the proteins in this group include the MRN (RAD50/MRE11/NBS1) complex, 
RAD51, the RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3), 
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RAD54 and RAD54B. The products of the breast cancer susceptibility genes, 
BRCA1 and BRCA2, are also involved in the modulation of the homologous 
recombination (Agarwal et al, 2006). 
When a DSB is detected, the initial damage response is mediated through the MRN 
complex and Ataxia telangiectasia mutated protein (ATM). The resection of DNA 
ends is required to generate 3´´ single-stranded DNA tails, which are the substrate for 
homologous recombination, because they are utilized for the nucleation of 
recombination factors on the DNA. RAD51 is an important protein at the core of 
homologous recombination.With the help of accessory factors, RAD51 polymerizes 
on the 3´´ tails to create a nucleoprotein filament. After a homology search, the 
nucleoprotein filament invades the target duplex at the site of homology to create a 
critical intermediate, the D-loop. This joint molecule between the broken sister 
chromatid and the intact sister chromatid is used as a template for DNA 
polymerases. In this way the sequence information that was lost in the initial 
processing of the DSB end is restored. The reaction is terminated with the ligation 
of DNA strands and the separation of the joint molecules to yield two intact DNA 
copies (Agarwal et al, 2006). 
 
Figure 6 Homologous recombination repair pathway (Modified from Christmann et al, 2003). 
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? Non-homologous end-joining repair (NHEJ) pathway 
The NHEJ repair pathway is based on the direct ligation of the two double-strand-
break ends and also involves numerous molecules, including LIG4 (O´Driscoll and 
Jeggo, 2006). During NHEJ, the two broken ends of DNA are simply pieced 
together, sometimes after limited processing of the DNA ends, resulting in quick, 
but error-prone, repair. HR is a more accurate method of repair as here information 
is copied from an intact homologous DNA duplex; however. As HR requires the 
presence of an intact sister chromatid, this method of repair can only operate in the 
S/G2 phases of the cell cycle in mammalian cells. NHEJ plays a major role in the 
elimination of DSBs during G1 phases of the cell cycle since HR is not efficient in 
this phase due to the lack of sister chromatids. NHEJ may be the main pathway of 
repair in mammalian cells especially in the G1 phase of the cell cycle. After DSB 
formation, the KU70/80 heterodimer binds the DNA ends. This facilitates the 
recruitment of DNA dependent protein kinase catalytic subunit (DNA-PKcs) to the 
DSB. This sequential binding of the proteins activates the phosphorylation function 
of DNA-PKcs, phosphorylating itself, the KU heterodimer, and other proteins 
involved in cell cycle regulation. It has been speculated that KU70/80 might 
function as an alignment factor that binds DSB ends, creating easy access for the 
DNA ligase IV-XRCC4 complex and increasing the efficiency and accuracy of 
NHEJ. The Ligase IV-XRCC4 complex then ligates the juxtaposed DNA ends. 
(Figure 7) (Agarwal et al, 2006; O´Driscoll and Jeggo, 2006).  
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Figure 7 Non-homologous end-joining repair pathway (Modified from O´Driscoll and Jeggo, 2006). 
 
Mismatch Repair (MMR) 
Unintentional errors, such as base–base mismatches, insertion/deletion loops, and 
heterologies, can be generated during DNA replication and recombination. To 
prevent genetic instability that may arise from such DNA intermediates, organisms 
have developed the MMR system. This pathway functions to either (1) repair the 
mismatches or insertions/deletions formed due to polymerase infidelity/slippage or 
(2) prevent the occurrence of heterologous (or non-conservative) DNA exchanges 
(i.e. recombination). Single nucleotide mismatches or single base pair 
insertions/deletions are recognized primarily by the heterodimer Msh2/Msh6 
(hMutSα), a complex composed of two distinct E. coli mutS homologs. An 
alternative heterodimer, Msh2/Msh3 (hMutSβ), targets insertion/deletion loops of 
>1, but <15, base pairs (larger loops are presumably substrates for NER). These 
“MutS” protein–DNA complexes then recruit the Mlh1/Pms2 heterodimer 
(hMutLα). Two other MutL complexes exist, i.e. Mlh1/Pms1 (hMutLβ) and 
Mlh1/Mlh3; a function for the former is presently unknown, while the latter is likely 
to contribute to the repair of insertion/deletion loops. The ensuing steps of human 
MMR are poorly defined, but in general, the mismatch or loop structure is 
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selectively excised from the newly synthesized strand of DNA and the genomic 
integrity restored. Enzymes found to contribute to the excision step in MMR include 
polymerase δ and Exo1. The PCNA-dependent polymerases (mainly polymerase δ), 
along with DNA ligase 1, are believed to execute repair synthesis and nick sealing, 
respectively, to complete the corrective process (Figure 8). By repairing base–base 
mismatches and insertion/deletion loops mistakenly introduced during DNA 
replication, the MMR pathway improves the fidelity of DNA synthesis 100–1000-
fold (Morehnveiser, 2002; Jun et al, 2006). Defects in this system dramatically 
increase mutation rates, accelerating the process of oncogenesis (Hoeijmakers, 
2001). Mutations in the genes of MMR have been linked to HNPCC. In particular, 
the mutator phenotype of individuals carrying mutations in the genes of MMR, with 
the vast majority occurring in MSH2 and MLH1, is severe microsatellite instability, 
i.e. the expansion/contraction of primarily mono- and di-nucleotide repeats 
(Morehnveiser, 2002).  
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Figure 8 Mismatch repair pathway (Modified from Hoeijmakers, 2001). 
 
Direct Repair (DR) 
In mammals, the only known DR pathway is comprised of a single protein (and thus 
a single gene), termed O6-alkylguanine (O6-AG) DNA alkyltransferase (AGT), 
encoded by O6-methylguanine (O6-MeG) methyltransferase (MGMT). This protein 
is an ubiquitous repair protein that plays a vital role in minimizing the mutagenic 
effects of alkylating agents, covalently binding at O6 position of guanine. AGT is 
able to act as a single protein that reverses alkylation damage (Margison and 
Santibanez-Koref, 2002). It transfers the alkyl group at the O6 position of guanine to 
a cysteine residue within its active site, leading to the direct restoration of the 
natural chemical composition of DNA without the need for genomic 
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“reconstruction” (Gerson, 2004) (Figure 9). However, this repair event results in the 
irreversible inactivation of the AGT protein, referred to as a “suicide” reaction. AGT 
has been shown to remove other alkyl groups in DNA as well, such as those formed 
at the phosphodiester linkages in the DNA backbone and, to a lesser extent, those 
generated at the O4 position of thymine. Deficiencies in MGMT can lead to an 
increase in mutations, in part because O6-MeG mispairs with thymine during DNA 
replication. Overexpression of MGMT reduces the risk of carcinogenesis and the 
risk of mutations after exposure to methylating agents, instead loss of MGMT is 
associated with increased carcinogenic risk and increased sensitivity to methylating 
agents (Gerson, 2004). 
 
 
A B 
 
Figure 9 Direct Repair process: A The AGT protein reverses alkylation damage; B If repair of the 
CH3-G lesion does not occur, a G→A transition mutation or a strand break can result (Modified from 
Gerson, 2004). 
 
1.4 Phenotypic effect of DNA repair polymorphisms 
 
The assessment of the individual DNA repair capacity represents a major task in the 
relationship to cancer etiology. The main difficulties are represented by still 
inadequate specific functional assays and lack of possibility to assess both intra-
individual and inter-individual variability (Berwick and Vineis, 2005). 
The polymorphisms of genes involved in different pathways of DNA repair may 
modulate the individual repair capacity in response to DNA damage, and may have 
an impact on individual genetic susceptibility to basically all type of cancer, 
including CRC (Friedberg, 2003, Spitz et al., 2003).  
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Over 520 amino acid substitution variants in 91 DNA repair genes have been 
identified in humans, while the number of other silent polymorphisms is constantly 
increasing, with many of them still unknown (Xi et al, 2004). An analysis of SNPs 
in 88 DNA repair genes and their functional evaluation, based on the conservation 
of amino acids among the protein family members, shows that approximately 30% 
of variants of DNA repair proteins are likely to affect substantially the protein 
function. It applies particularly for polymorphisms in XRCC1 (Arg280His and 
Arg399Gln), and XRCC3 (Thr241Met) (Savas et al., 2004). Unfortunately, for many 
polymorphisms the functional significance/phenotypic changes are still not 
experimentally shown in the general population. There are relatively few studies, 
sometimes based on a small number of observations and investigating few 
polymorphisms. Susceptibility towards ionizing radiation sensitivity, as measured 
by prolonged cell cycle G2 delay, was significantly affected by amino acid 
substitution variants in XRCC1 Arg194Trp, Arg399Gln and APE1 Asn148Glu 
polymorphisms (Hu et al., 2001). Using the cytogenetic challenge assay, XRCC1 
399Gln and XRCC3 241Met variant alleles were associated with significant increase 
in chromosomal deletions as compared with the corresponding homozygous wild 
types (Au et al., 2003). Individuals with the XRCC1 194ArgArg genotype exhibited 
significantly higher values of chromosomal breaks than those with variant Trp 
allele, suggesting a protective effect of this allele. On the other hand, variant Gln 
allele in XRCC1 Arg399Gln was significantly associated with an increase in 
chromosomal breaks. These data are biologically plausible, since codon 399 is 
located within the BRCA1 C-terminus functional domain and codon 194 is in the 
linker region of the XRCC1 N-terminal functional domain (Wang et al., 2003). 
Three studies using different approaches have found a functional impact of hOGG1 
Ser326Cys polymorphism (Kohno et al., 1998, Chen et al., 2003, Yamane et al., 
2004), but other studies (reviewed by Weiss et al., 2005) did not find any conclusive 
result for hOGG1 genetic polymorphisms. hOGG1 Ser326Cys polymorphism has 
also been found to affect the glycosylase function due to the localization and 
phosphorylation status (Luna et al., 2005).  
In our recent study, the influence of several polymorphisms in different DNA repair 
pathways was investigated in association with individual DNA repair activity (i.e. 
the capacity to repair both γ-irradiation-specific induced- and oxidative-induced 
DNA damage) in a general healthy Central European population (n=244). 
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Irradiation-specific DNA repair rates were significantly decreased in individuals 
with XRCC1 Arg399Gln homozygous variant genotype, consistent with a role of the 
gene in the repair pathway. In addition, the capacity to repair oxidative DNA 
damage was significantly decreased in individuals with hOGG1 Ser326Cys 
homozygous variant genotype. The relationships between polymorphisms of XRCC1 
Arg399Gln and APE1 Asn148Glu and functional outcomes have recently been 
highlighted in healthy subjects. Increasing number of variant alleles for both XRCC1 
Arg399Gln and APE1 Asn148Glu polymorphisms resulted in a significant decrease 
of irradiation-specific repair rates, reflecting a gene-gene interaction (Vodicka et al, 
2006). Irradiation-specific repair rates also decreased with increasing number of 
variant alleles in XRCC1 Arg399Gln in combination with variant alleles for other 
XRCC1 polymorphisms, Arg194Trp and Arg280His. Similarly, variant alleles of 
hOGG1 Ser326Cys and APE1 Asn148Glu exhibited a significantly decreased repair 
of DNA oxidative damage (Vodicka et al., 2006). The results of such tests should 
enable a more meaningful choice of genes/polymorphisms for association studies, 
though there is a still not sufficient evidence for an accurate prediction on the 
individual DNA repair capacity.  
Many DNA repair gene variants have been studied extensively in the context of 
cancer susceptibility. In this context, many case-control studies have focused on 
identifying possible associations of SNPs in candidate DNA repair genes with 
altered risk for several different cancer sites. The assumption is that DNA repair is 
likely to work in a rather non-specific manner for different carcinogens and different 
cancers. Several reviews have recently tried to summarize the main results of the 
published studies on DNA repair genetic polymorphisms in association with cancer 
(Goode et al., 2002, Hung et al., 2005, Benhamou and Sarasin, 2005, Weiss et al., 
2005, Manuguerra et al, 2006). However, the outcomes from epidemiological 
studies are not so clear. Only in the case of few genes, like hOGG1, XRCC1 for 
BER and XPD for NER, consistent evidences for the association of particular 
genetic polymorphisms with specific cancers have been found. For instance, the 
variant CysCys genotype of hOGG1 Ser326Cys polymorphism seems to be 
associated with an increased risk of lung cancer, esophagus, and prostate cancer 
(Goode et al., 2002, Hung et al., 2005, Weiss et al., 2005), and SNPs of XPD 
(Benhamou and Sarasin, 2005, Manuguerra et al., 2006) have been significantly 
associated with skin, breast and lung cancer. On the other hand, polymorphisms like 
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those of XRCC3 gene seem to have no association with any cancer risk, despite the 
importance of this gene in DSB repair pathway.  
 
1.5 DNA repair poymorphisms and susceptibility to CRC 
 
Cancer-related genes have traditionally been classified as protooncogenes and 
tumor-suppressor genes. More recently, these genes have been reclassified as 
caretakers, gatekeepers and landscapers (Dean, 2003). Although this new 
classification was made in the context of high-penetrant genes and familial cancer 
syndromes, the concept is also applicable to low-penetrant genes and gene-
environment interactions. Caretakers are responsible for maintaining genomic 
integrity (e.g., DNA repair, metabolic activation or detoxification), and when 
mutated, they increase the probability of mutation in other genes. Gatekeepers are 
responsible for cell cycle control, signal transduction and replication. When 
mutated, these genes have the ability for selective clonal expansion. Landscapers are 
concerned with signaling to adjacent cells (Ahmned, 2006; Figure 3). 
The effect of food mutagens on caretaker and gatekeeper genes can theoretically be 
modulated by interindividual variation in the function of any enzyme that is 
involved in DNA damage and response (i.e., metabolic activation or detoxification, 
DNA repair, cell cycle control, differentiation, apoptosis, etc.). 
For cancer-causing food mutagens, inter-individual variation is governed by genetic 
polymorphism, in which the frequency of the genetic variant in the population of 
interest is >1%. Sporadic cancer risk may be modified by polymorphisms in low-
penetrant genes, more often in the context of exposure and not as a main effect. 
Although the increase in cancer risk associated with polymorphism in low-penetrant 
genes is small, the attributable risk in the population is large due to the high 
frequency of the variant (Ahmed, 2006). 
Mutations in MMR genes are known to segregate in families with HNPCC 
(Peltomaki, 2001). However, the link between DNA repair and CRC development is 
even stronger as demonstrated by the association of germline mutations in MUTYH, 
a BER gene encoding a DNA glycosylase, with a predisposition to multiple 
colorectal adenomas and carcinomas (Al-Tassan et al., 2002). 
Over the last 10 years, a growing number of studies have investigated the role of 
DNA repair in the CRC onset. In Tables 1-5 are presented in summary the main 
 24
 25
results from association studies between genetic polymorphisms in the main DNA 
repair pathways and risk of CRC/adenomas. 
The outcomes from association studies on polymorphisms of NER genes do not 
show any strong and straight association with CRC risk (Table 1). The most 
frequently studied, XPD Lys751Gln, provided significant associations only with 
adenomas. In CRC development the susceptibility may play a more relevant role in 
the stage of adenomas, which preceeds the onset of cancer. For BER pathway, the 
majority of studies analyzed variants in XRCC1 (Table 2).
Table 1. Association studies between genetic polymorphisms in NER genes and risk of CRC/adenomas  
Reference Genes (polymorphisms) Cases Controls Ethnicity 
(Country) 
Associations  
 
Interactions 
Berndt et al. 
2006 
XPA 
(3´UTR C→G) 
XPB 
(487bp 3' of STP, G→A, IVS6-108, 
A→C) 
XPC 
(Arg492His, Ala499Val, Arg687Arg, 
Lys939Gln) 
XPD  
(Lys751Gln, IVS19-70) 
XPF  
(Arg415Gln, Ser662Pro) 
XPG 
(Cys529Ser, Asp1104His) 
CSB 
(Met1097Val, Arg1213Gly, 
Arg1230Pro) 
LIG1 
(5´UTR C→T) 
ERCC1 
(Gln504Lys, 19716 C →G) 
RAD23B 
(Ala249Val) 
RPA2 
(3´UTR T→C) 
250 
carcinomas  
2224 no 
history of 
cancer  
American 
mixed 
(Caucasian 
98%) (USA) 
CSB 1097Val and 
1213Gly alleles 
associated with ↑ 
CRC risk 
 
XPC 492His allele 
associated with ↑ 
CRC risk 
 
XPC haplotype 
containing 492His 
allele associated with 
↑ CRC risk 
 
SNP-SNP interaction between CSB 
1097Val and XPC 492His alleles and 
CSB 1213Gly and XPC 492His alleles 
slightly ↑ CRC risk 
 
CSB 1097Val and 1213Gly alleles 
associated with ↑ CRC risk among 
individuals with a first-degree relative 
with CRC 
 
No interactions with age at diagnosis, 
gender, smoking habit, red meat intake, 
folate intake, and body mass index 
Goodman et 
al. 2006 
XPD  
(Asp312Asn) 
XPF  
(Arg415Gln, Glu875Gly) 
XPG 
(Cys529Ser, Asp1104His) 
216 
carcinomas 
(males) 
255 no 
history of 
cancer 
(males) 
Caucasian 
and African 
American 
(USA) 
No association of 
single SNP 
No interactions between NER (or other 
DNA repair) polymorphisms 
Huang et al. XPD 772 high-risk 777 negative American No association of Smokers with XPC haplotype (Arg, Ala, 
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2006 (Asp312Asn, Lys751Gln) 
XPC 
(Arg492His, Ala499Val, Lys939Gln) 
RAD23B 
(Ala249Val) 
CSB 
(Met1097Val, Arg1230Pro, 
Gln1413Arg) 
CCNH 
(Val270Ala) 
XPF  
(Pro379Ser, Arg415Gln)  
XPG 
(Met254Val, Cys529Ser, 
Asp1104His) 
adenomas 
 
to 
colonscopy 
screening 
mixed 
(USA) 
single SNP 
 
 
and Gln) associated with ↑ risk of high-
risk adenomas  
 
No interactions with age, gender, and 
ethnicity 
Moreno et al. 
2006 
ERCC1 
(19716 G→C, 19007 T→C, 17677 
A→C, 
15310 G→C, 8092 C→A) 
XPD  
(Asp312Asn, Lys751Gln) 
XPF  
(Pro379Ser, Arg415Gln) 
XPG 
(335 T→C) 
377 
carcinomas 
329 hospital 
healthy 
Caucasian 
(Spain) 
 
ERCC1 17677C 
allele associated with 
↑ CRC risk in an 
additive model  
 
ERCC1 haplotype 
(19716C, 19007C 
and 17677C) 
associated with ↑ 
CRC risk 
No interactions with age 
Skjelbred et 
al. 2006 (a) 
XPD 
(Lys751Gln) 
 
157 
carcinomas 
983 adenomas 
(227 high-risk 
and 756 low-
risk) 
399 negative 
to 
colonscopy 
screening 
Caucasian 
(Norway) 
XPD 751Gln allele 
associated with ↑ risk 
of low-risk adenoma 
No interactions with smoking habit 
Skjelbred et 
al. 2006 (b) 
 
ERCC1 
(Asn148Asn) 
156 
carcinomas 
981 adenomas 
(227 high-risk 
399 negative 
to 
colonscopy 
screening 
Caucasian 
(Norway) 
No association of 
single SNP 
 
No interactions with smoking and alcohol 
habits 
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and 754 low-
risk) 
Bigler et al. 
2005 
XPD 
(Asp312Asn, Lys751Gln) 
XPG  
(Asp1104His) 
694 
(384 
adenomatous 
polyps, 191 
hyperplastic 
polyps, 119 
both types) 
621 negative 
to 
colonscopy 
screening 
Afroamerica
n and 
Caucasian 
(USA) 
 
No association of 
single SNP 
 
Combination of XPD 
312Asn and 751Gln 
alleles associated 
with ↑ adenoma risk 
 
XPG 1104HisHis 
genotype associated 
with ↓ risk of 
hyperplastic polyps 
Heavy smokers with XPD combined 
homozygous variant genotypes or XPG 
1104 AspAsp genotype had an ↑ risk of 
adenomatous polyps  
 
XPG 1104HisHis genotype associated 
with ↓ risk of hyperplastic polyps in 
young individuals (<60yrs) 
 
No interactions with gender, meat 
consumption, and alcohol and vitamin 
intakes  
Starinsky et 
al. 2005 
XPD 
(Lys751Gln) 
456 
carcinomas 
87 hospital 
healthy 
Jewish (64% 
Ashkenazi) 
(Israeli) 
No association of 
single SNP 
 
XPD 751Gln allele associated with age at 
diagnosis in Ashkenazi subset only 
Yeh et al. 
2005 (a, b) 
Yeh et al. 
2006 
XPD 
(Lys751Gln) 
 
727 
carcinomas 
736 negative 
to 
colonscopy 
screening 
Asian 
(Taiwan) 
No association of 
single SNP 
 
 
↑ CRC risk for combinations of XPD, 
XRCC3, and XRCC1 genotypes with OR 
>1, particularly for younger individuals 
(<61yrs) and for rectum cases 
Combinations of XPD and CYP1A1*2C 
and GSTT1 deletion high-risk genotypes 
associated with ↑ CRC risk 
No interactions for XPD polymorphism 
with smoking habit, alcohol and meat 
intake, or vegetable/fruit and fish/shrimp 
consumption 
Mort et al. 
2003 
XPD (exon 6, exon 22, Lys751Gln) 
ERCC1 exon 4 
XPG (Asp1104His) 
XPF (Glu875Gly) 
45 carcinomas 71 hospital 
healthy (not 
for all 
genes) 
Caucasians 
(?) 
(England) 
No association of 
single SNP 
 
 
(?) not fully specified in the study
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For XRCC1 Arg399Gln, there is a slight prevalence of studies with an increased 
CRC risk in association with the variant Gln allele, while for adenoma cases the 
same allele shows a decreased risk. A clear interpretation of the role of this 
polymorphism is precluded by facts that the CRC studies are conducted on different 
ethnic groups and, unfortunately, positive associations emerge mostly in studies 
with smaller sample-size. This precludes a clear interpretation of the role of this 
polymorphism. For two other XRCC1 SNPs (Arg194Trp, Arg280His), significant 
associations have been observed only in combinations, suggesting a more relevant 
role of particular haplotypes rather than single SNPs. The second most frequently 
analysed SNP, OGG1 Ser326Cys, provided inconclusive outcomes. The variant 
allele has been described in association with either increased (Goodman et al, 2006; 
Moreno et al, 2006) or decreased CRC risk (Hansen et al, 2005), and also in no 
association at all (Kim et al, 2003). Several studies analysed interactions between 
BER SNPs with modifiers (age, gender, smoking habits, alcohol and meat 
consumption). Overall, age stratification appears to be important: an influence of 
genetic polymorphisms seems to be more relevant in individuals with a younger age 
at the diagnosis (i.e. below 60 years). 
No strong associations emerged for DSB gene polymorphisms from the reviewed 
studies (Table 3). XRCC3 Thr241Met polymorphism was associated with CRC risk, 
but with opposite directions, as reported in (Mort et al, 2003; Krupa and Blasiak, 
2004; Jin et al, 2005). Conflicting data from association studies between 
polymorphisms and cancer susceptibility are not unusual and often result from an 
insufficient sample size, as e.g. Mort et al (2003) and Krupa and Blasiak (2004) 
investigated far less than 100 patients. No main interactions of modifiers (i.e. 
smoking, alcohol, and meat consumption, fatty acids and antioxidants intake) 
emerge with SNPs in DSB repair genes. In the study of Jin et al. (2005), the carriers 
of XRCC3 241Met allele non-smokers and non-alcohol drinkers, showed an 
increased CRC risk (adjusted OR 4.85, 95% CI: 1.59–14.76 among non-smokers 
and adjusted OR 3.72, 95% CI: 1.48–9.39 among non-alcohol drinkers, 
respectively). In this case, the stratification reduced drastically the number of 
observations within each group. Yeh et al. (2005a, b and 2006) did not find any 
association for XRCC3 Thr241Met, but a stratification of the patients for meat 
consumption revealed that individuals with 241ThrThr genotype and low consumers 
Table 2. Association studies between genetic polymorphisms in BER genes and risk of CRC/adenomas  
Reference Genes (polymorphisms) Cases Controls Ethnicity 
(Country) 
Associations (Main results) Interactions 
Goodman et 
al. 2006 
OGG1 
(Ser326Cys) 
XRCC1  
(Arg194Trp, Arg399Gln) 
216 carcinomas 
(males) 
255 no history of 
cancer (males) 
Caucasian and 
African American 
(USA) 
Significant Ptrend for OGG1 
(Ser326Cys) 
 
No interactions between BER (or 
other DNA repair) 
polymorphisms 
Moreno et al. 
2006 
OGG1 
(Ser326Cys) 
LIG3 
(Lys811Thr, Arg780His) 
APEX  
(Gln51His, Asp148Glu) 
POLB 
(Pro242Arg) 
XRCC1 
(Arg194Trp, Arg280His, 
Arg399Gln) 
PCNA  
(1876 A→G) 
MUTYH 
(Tyr165Cys, Gly382Asp) 
377 carcinomas 329 hospital 
healthy 
Caucasian 
(Spain) 
 
OGG1 326C allele associated 
with ↑ CRC risk  
 
 
POLB 242Arg rare allele 
associated with ↓ CRC risk (no 
homozygous variant found) 
OGG1 326CysCys genotype 
associated with ↑ CRC risk in 
young individuals 
 
XRCC1 194Trp and 280His 
minor alleles associated with a ↓ 
CRC risk in young individuals 
 
Skjelbred et 
al. 2006 (a) 
XRCC1 
(Arg194Trp, Arg280His, 
Arg399Gln) 
157 carcinomas 
983 adenomas 
(227 high-risk and 
756 low-risk) 
399 negative to 
colonscopy 
screening 
Caucasian 
(Norway) 
XRCC1 280His allele associated 
with ↑ adenoma risk 
 
XRCC1 399Gln allele associated 
with ↓ risk in the high-risk 
adenoma group 
No interaction with smoking 
habit  
Hansen et al. 
2005 
OGG1 
(Ser326Cys) 
166 carcinomas 
974 adenomas  
 
397 negative to 
colonscopy 
screening 
Caucasian 
(Norway) 
OGG1 326Cys allele associated 
with ↓ carcinoma risk  
 
Hong et al. 
2005 
XRCC1 
(Arg194Trp, Arg280His, 
Arg399Gln) 
209 carcinomas 209 hospital 
healthy 
Asian  
(South Korea) 
XRCC1 399Gln allele associated 
with ↑ CRC risk 
 
↑ CRC risk associated with 
alcohol intake in combined 
alleles 194Trp-280Arg-399Arg, 
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The combined alleles XRCC1 
194Trp-280Arg-399Gln 
associated with ↑ CRC risk  
194Trp-280His-399Arg and 
194Arg-280Arg-399Gln 
 
No interaction with smoking, 
dietary habits and physical 
activity 
Stern et al. 
2005 
XRCC1  
(Arg194Trp, Arg399Gln) 
753 adenomas 799 hospital 
healthy 
Caucasian, African 
American, Latinos, 
Asian/Pacific 
Island  
(USA) 
XRCC1 399GlnGln genotype 
associated with ↓ adenoma risk 
 
XRCC1 194ArgArg and 
399GlnGln combined genotypes 
associated with ↓ adenoma risk 
↑ adenoma risk associated with 
high monounsaturated fatty acid 
intake, in individuals with 
XRCC1 194ArgArg and 
399GlnGln combined genotypes  
 
No interaction with 
polyunsaturated fatty acid intake 
and antioxidant intake 
Yeh et al. 
2005 (a, b) 
Yeh et al. 
2006 
XRCC1 
(Arg399Gln) 
727 carcinomas 736 negative to 
colonscopy 
screening 
Asian 
(Taiwan) 
No association of single SNP 
 
XRCC1 399Arg allele associated 
with ↑ CRC risk for young 
individuals (<61yrs) and for 
rectum cases 
 
↑ CRC risk for combinations of 
XRCC1, XPD and XRCC3 
genotypes, particularly for 
younger individuals (<61yrs) 
and for rectum cases 
 
No interactions with smoking 
habit, alcohol and meat intake, 
or vegetable/fruit and 
fish/shrimp consumption 
Kim et al. 
2004a 
OGG1 
(Arg154His) 
500 carcinomas 527 hospital 
healthy 
Asian  
(South Korea) 
OGG1 154His allele associated 
moderate ↑ CRC risk 
 
Krupa et 
Blasiak. 2004 
XRCC1 
(Arg399Gln) 
51 carcinomas 100 hospital 
healthy 
Caucasian 
(Poland) 
XRCC1 399Gln allele (?) weakly 
associated with ↑ CRC risk  
Gene-gene interaction between 
the XRCC3 241MetMet and the 
XRCC1 399ArgArg genotypes 
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slightly ↑ CRC risk 
Kim et al. 
2003 
OGG1 
(Ser326Cys) 
125 carcinomas 247 cancer-free Asian  
(South Korea) 
No association of single SNP 
 
OGG1 326CysCys genotype 
associated with ↑ CRC risk in 
group with higher meat intake. 
 
Smokers with OGG1 326CysCys 
genotype moderately associated 
with ↑ CRC risk 
 
No interactions with alcohol 
consumption, vegetable and 
soybean intake, physical activity 
and family history of cancer 
Mort et al. 
2003 
XRCC1, exon 17 
 
45 carcinomas 71 hospital healthy 
(not for all genes) 
Caucasian (?) 
(England) 
No association of single SNP 
 
 
Abdel-
Rahman et al. 
2000 
XRCC1  
(Arg194Trp, Arg399Gln) 
48 carcinomas 48 healthy 
population 
(?) 
(Egypt) 
XRCC1 399Gln allele associated 
with ↑ CRC risk  
XRCC1 399Gln allele associated 
with ↑ CRC risk only in young 
individuals (<40yrs), and mainly 
in urban resident individuals 
(?) not fully specified in the study 
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Table 3. Association studies between genetic polymorphisms in Double-strand break repair genes and risk of CRC/adenomas   
Reference Genes 
(polymorphisms) 
Cases Controls Ethnicity 
(Country) 
Associations (Main results) Interactions 
Goodman et 
al. 2006 
XRCC3 
(Thr241Met) 
NBS1 
(Glu185Gln) 
216 carcinomas 
(males) 
255 no history of 
cancer (males) 
Caucasian and 
African American 
(USA) 
No association of single SNP 
 
No interactions between DSB 
(or other DNA repair) 
polymorphisms 
Skjelbred et 
al. 2006 (a) 
XRCC3 
(Thr241Met) 
 
157 carcinomas 
983 adenomas 
(227 high-risk and 
756 low-risk) 
 
399 negative to 
colonscopy 
screening 
Caucasian 
(Norway) 
No association of single SNP 
 
No interactions with smoking 
habit or alcohol consumption 
Moreno et 
al. 2006 
XRCC2  
(Arg188His) 
XRCC3 
(Thr241Met) 
XRCC9 
(Thr297Ile) 
377 carcinomas  329 hospital healthy Caucasian 
(Spain) 
 
No association of single SNP 
 
No interaction with age 
Jin et al. 
2005 
XRCC3 
(Thr241Met) 
140 carcinomas 280 cancer-free Asian 
(China) 
XRCC3 241Met allele associated 
with ↑ CRC risk  
XRCC3 241Met allele in older 
individuals associated with ↑ 
CRC risk 
 
Non smokers and non using 
alcohol individuals with XRCC3 
241Met allele associated with ↑ 
CRC risk  
 
No interaction with gender 
Stern et al, 
2005 
XRCC3 
(Thr241Met) 
753 adenomas 799 hospital healthy Caucasian, African 
American, Latinos, 
Asian/Pacific 
Island 
(USA) 
No association of single SNP 
 
No interactions with poly and 
mono unsaturated fatty acids and 
antioxidant intake 
Yeh et al. XRCC3 776 carcinomas 736 negative to Asian No association of single SNP XRCC3 241Thr allele associated 
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2005 (a, b) 
Yeh et al. 
2006 
(Thr241Met) 
 
colonscopy 
screening 
(Taiwan)  with ↑ CRC risk in low meat 
consumption individuals, 
particular in rectum cases 
 
↑ CRC risk for combinations of 
XRCC3, XPD and XRCC1 
genotypes with OR >1, 
particularly for younger 
individuals (<61yrs) and for 
rectum cases 
 
Combinations of XRCC3 
T241Met and CYP1A1*2C high-
risk genotypes  associated ↑ 
CRC risk in women 
 
No interactions with smoking 
habit, alcohol intake and 
vegetable/fruit and fish/shrimp 
consumption 
Krupa et 
Blasiak. 
2004 
XRCC3 
(Thr241Met) 
51 carcinomas  100 hospital healthy Caucasian 
(Poland) 
XRCC3 241MetMet genotype 
strongly associated with ↑ CRC 
risk  
 
Gene-gene interaction between 
XRCC3 241MetMet and XRCC1 
399ArgArg genotypes slightly ↑ 
CRC risk  
Tranah et al. 
2004 
XRCC2  
(Arg188His), 
XRCC3 
(Thr241Met, 4541 
A→G, 17893 A→G ) 
932 adenomas 1282 cancer-free Caucasian (?) 
(USA) 
 
No association of single SNP 
 
No interactions of alcohol and 
smoking habit, although both 
confounders increased OR of 
genotypes 
 
No interactions with plasma and 
dietary folate 
Mort et al. 
2003 
XRCC3 
(Thr241Met) 
123 carcinomas 128 hospital healthy Caucasian (?) 
(England) 
Moderate association of 241Thr 
allele with ↑ CRC 
 
(?) not fully specified in the study
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of meat had an increased risk of CRC (OR, 2.34; 95% CI, 1.28-4.29, 
Pinteraction=0.02). Enhanced risk was particularly pronounced in rectal cancer 
patients. In Yeh et al (2006), the combination of XRCC3 Thr241Met wild type 
genotype and CYP1A1*2C variant GG genotype was associated with increased 
CRC risk in women (OR, 3.1, 95% CI, 1.3-7.0, P<0.01). In this case the 
stratification for dietary/lifestyle risk factors and gender was justified by the large 
size of the cohort (>700 individuals). The effect of age did not emerge, except for 
Jin et al (2005), where XRCC3 241Met allele was associated with CRC risk 
among older individuals (>60 years).  
There are still limited data on MMR polymorphisms and CRC risk for drawing 
any conclusion at present (Table 4). Berndt et al (2007) found significant 
associations with hMSH3 SNPs and Yu et al (2006) found a possible modifying 
effect of smoking for hyperplastic polyp risk in hMLH1 –93A carriers. Otherwise, 
the studies did not reveal clearly positive associations. Interestingly, 
polymorphisms in EXO1 seem to modulate inversely CRC risk, but only one 
study is available (Yamamoto et al, 2005) and these results should be confirmed 
on larger, ethnically homogeneous populations.  
Four studies have analysed MGMT polymorphisms in relation to CRC risk (Table 
5). The association between MGMT Ile143Val and Leu84Phe polymorphisms and 
risk of CRC was assessed in two American nested case-control studies (Tranah et 
al, 2006). The first population consisted of 197 women with CRC and 2,500 
cancer-free women, while the second included 271 male CRC cases and 451 
cancer-free men as control group. Cases were matched with controls for age and 
smoking history. A significant inverse association between the MGMT 143Val 
allele and CRC risk was found only in women. No association was found in the 
other studies on MGMT polymorphisms (Bigler et al, 2005; Goodman et al, 2006; 
Moreno et al, 2006), however, the data available are still relatively scarce, 
precluding any conclusion. 
Table 4. Association studies between genetic polymorphisms in Mismatch repair genes and risk of CRC/adenomas   
Reference Genes 
(polymorphisms) 
Cases Controls Ethnicity 
(Country) 
Associations (Main 
results) 
Interactions 
Berndt et al. 
2007 
hMLH1  
(Ile219Val) 
hMSH3  
(Thr1036Ala, 
Arg940Gln) 
hMSH6  
(Gly39Glu) 
 
237 carcinomas 2189 no history of 
cancer 
American mixed 
(Caucasian 98%) 
(USA) 
hMSH3 1036Ala allele 
associated with ↑ CRC risk 
hMSH6 39GluGlu genotype 
associated with ↑ risk of 
rectal cancer 
hMSH3 haplotype 
containing both 940Gln and 
1036Ala alleles associated 
with ↑ CRC risk 
hMSH3 1036Ala allele 
associated with ↑ risk of CRC in 
interaction with meat intake ≥10 
g/day 
 
hMSH3 haplotype containing 
1036Ala allele associated with ↑ 
CRC risk among individuals 
with meat intake ≥10 g/day 
 
No interactions with gender, 
smoking habit, folate intake, 
alcohol consumption, and family 
history 
Yu et al. 
2006 
hMLH1  
(-93G→A, Ile219Val) 
hMSH6  
(Gly39Glu) 
719 (401 
adenomas,195 
hyperplastic polyps, 
123 both types) 
624 negative to 
colonscopy 
screening 
Caucasian-
American (97%) 
(USA) 
 
No association of single 
SNP 
hMLH1-93 A allele is associated 
with ↑ risk of hyperplastic 
polyps associated with smoking. 
 
Yamamoto 
et al. 2005 
EXO1 
(Thr439Met, 
Pro757Leu) 
102 carcinomas 110 healthy 
population 
Asian 
(Japan) 
EXO1 439Met allele 
associated with ↑ CRC risk 
 
EXO1 757 LeuLeu genotype 
associated with ↓ CRC risk 
 
EXO1 439MetMet and 
439ThrMet, with EXO1 
757ProLeu genotypes are 
associated with ↑ CRC risk 
Kim et al. 
2004b 
hMLH1 
 (Ile219Val, 
Val384Asp) 
hMSH2 
 (Leu390Phe, gIVS12) 
107 carcinomas  330 healthy 
controls and 107 1st 
degree relatives of 
cases 
Asian 
(Korea) 
No association of single 
SNP 
 
Peterlongo et 
al. 2003 
hMSH6  
(Val509Ala, -159 
C→T) 
167 carcinomas  190 healthy 
controls  
American Jews  
(USA) 
No association of single 
SNP 
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Table 5. Association studies between genetic polymorphisms in MGMT gene (Direct repair) and risk of CRC/adenomas   
Reference Genes 
(polymorphisms) 
Cases Controls Ethnicity 
(Country) 
Associations (Main 
results) 
Interactions 
Goodman et 
al. 2006 
MGMT 
(171 C→T) 
216 carcinomas 
(males) 
255 no history of 
cancer (males) 
Caucasian and 
African American 
(USA) 
No association of single 
SNP 
No interactions between MGMT 
and other DNA repair SNPs 
Moreno et 
al. 2006 
MGMT 
(171 C→T, Leu84Phe, 
Ile143Val) 
377 carcinomas  329 hospital 
healthy 
Caucasian 
(Spain) 
 
No association of single 
SNP 
 
No interactions with age 
Bigler et al. 
2005 
MGMT 
(Leu84Phe, Ile143Val) 
694 
(384 adenomatous 
polyps, 191 
hyperplastic 
polyps, 119 both 
types) 
601 negative to 
colonscopy 
screening 
African American 
and Caucasian 
(USA) 
 
No association of single 
SNP 
MGMT combined genotypes 
showed an interaction with 
smoking habit 
 
No interactions with age, gender, 
meat consumption, and alcohol and 
vitamin intake 
Tranah et al. 
2006 
MGMT 
(Leu84Phe, Ile143Val) 
197 carcinomas 
(females) 
 
 
451 carcinomas 
(males) 
2500 cancer-free 
(females) 
 
451 cancer-free 
(males) 
Caucasian-
American (97%) 
(USA) 
MGMT 143Val allele 
associated with ↓ risk of 
CRC in cohort of women 
 
No association of single 
SNP in men cohort 
MGMT 84Phe allele associated 
with ↑ risk of CRC among women 
consuming ≥0.5 drink/day. No 
interaction between alcohol intake 
and MGMT Ile143Val SNP 
 
MGMT 84Phe and 143Val alleles 
associated with ↓ risk of CRC 
among women with BMI ≥25 
 
MGMT 84LeuLeu genotype and 
use of postmenopausal hormone 
associated with ↑ risk of CRC  
 
No interactions with smoking 
habit, folate, and processed meat 
intake in women. 
No interactions with BMI, alcohol 
consumption, and smoking history 
in men 
1.6 Pharmacogenomics and CRC: prognosis and individual susceptibility. 
 
The importance of individual susceptibility is most likely not limited only to the 
onset of CRC, but involves also prognosis and efficacy of chemotherapy and 
radiation therapy. The prognosis of a patient with CRC is highly impacted by 
various factors at the time of diagnosis, such as localization of the tumor, quality of 
surgical procedures, gender, age, and patient’s overall performance status 
(Stoehlmacher and Lenz, 2003). In addition to the clinical/pathological staging (a 
major factor for the success of surgical operations, postoperative management and 
survival expectancies), the possibility to identify cancer patients with high 
likelihood of recurrence, or experiencing clinical toxicity, has a significant impact 
on the development of more efficient/less toxic treatment strategies. Inter-individual 
variations in response and toxicity to a particular therapy may be due to genetic 
alterations in drug targets, metabolizing enzymes, efflux and DNA repair systems at 
the genomic, mRNA and protein levels. Thus, the main aim of pharmacogenetics 
screening before treatment is to identify patients who may respond to particular 
chemotherapeutic agents and patients who may encounter increased toxicity to the 
same agents on the base of patient’s genetic information (Lenz, 2003, Russo et al., 
2005). 
Determination of genetic polymorphisms is becoming important as a possible 
method for helping the oncologist to decide on a more specific, personalized 
therapeutic approach and to provide crucial information for drug development. 
Currently, only few promising polymorphisms have been identified, or at least 
tested, for chemotherapy success and toxicity in CRC treatment. The most studied 
polymorphisms are in the thymidilate synthase (TS) gene, which is the main target 
of chemotherapeutic agents such as 5-fluorouracil and capecitabine, widely used for 
CRC treatment (Stoehlmacher et al., 2003). DNA repair genetic polymorphisms 
have also been investigated in the case of treatments based on platinum agents, 
cisplatin and oxaliplatin, because an increased DNA repair capacity plays an 
important role in chemoresistance to platinum-based compounds (Lenz, 2003). 
DNA adducts caused by the bulky 1,2-diamino-cyclohexane ring containing 
oxaliplatin are considered to mediate increased cytotoxicity and more effectively 
block DNA replication in comparison to other platinum agents. Oxaliplatin-based 
therapy, in particular, has been shown to be successful in concomitance with other 
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agents like 5-fluorouracil (Stoehlmacher et al., 2003). Enzymes of NER pathway are 
thought to repair DNA damage caused by platinum agents and several studies 
demonstrated the inverse relationship between impaired DNA repair capacity and 
increased response rates to platinum drugs (Kweekel et al., 2005). 
Three studies addressed the possible modulating role of different DNA repair 
polymorphisms in relation to the response to 5-fluorouracil/oxaliplatin treatments. In 
73 patients with metastatic CRC, three common XPD polymorphisms (Cys156Ala, 
Asp312Asn, and Lys751Gln) were investigated for their possible impact on the 
outcome of the therapy (Park et al., 2001). Among those tested for the Lys751Gln 
polymorphism, 24% (5 of 21) patients with the 751LysLys genotype responded, 
versus 10% (4 of 39) and 10% (1 of 10) of those with the 751LysGln and 
751GlnGln genotypes (P = 0.015). The median survival for those with the 
751LysLys genotype was 17.4 (95% CI 7.9-26.5) versus 12.8 (95% CI 8.5-25.9) and 
3.3 (95% CI 1.4-6.5) months for patients with the heterozygous and homozygous 
variant genotype, respectively (P=0.002). The other two investigated XPD 
polymorphisms were neither associated with any response to 5-
fluorouracil/oxaliplatin nor with survival. Stoehlmacher et al (2001), in 61 patients 
(same therapy as above) observed that individuals with at least one Gln variant 
allele in XRCC1 Arg399Gln polymorphism were at increased risk of chemotherapy 
failure. The role of two polymorphisms in the ERCC1 gene (in codon 118 and in 3'-
untranslated region) was recently evaluated for the clinical outcome to platinum-
based chemotherapy in 106 patients with advanced refractory CRC (Park et al. 
2003). ERCC1 codon 118 SNP causes a C→T substitution, but codes for the same 
amino acid, asparagine, and may be associated with different ERCC1 gene 
expression. ERCC1 3'-untranslated region may affect mRNA stability. The authors 
found a significant association between the ERCC1 codon 118 polymorphism and 
clinical outcome: patients with the CC genotype had a median survival of 15.3 
months (95% CI, 6.0-12.1), whereas 11.1 months (95% CI, 5.8-16.2) for those with 
CT and TT genotypes. The ERCC1 codon 118 polymorphism may be a useful 
predictor of clinical outcome in advanced CRC cases. Viguier et al. (2005), 
analyzed 91 patients treated for metastatic CRC in a retrospective study, and 
observed a higher response to combined chemotherapy of oxaliplatin/5-fluorouracil 
in individuals with variant T allele in ERCC1 codon 118 polymorphism. No 
significant differences were detected when patients were treated only with 5-FU or 
 39
with 5-FU and irinotecan. Shirota and collaborators (2001), have shown that CRC 
patients with high ERCC1 gene expression levels, treated with 5-FU/oxaliplatin, 
exhibited shorter surviving period than those with low expression levels. In the 
recent study, using univariate analysis, adjusted for age, sex, and Duke's stage, 
ERCC1 19007T>C was associated with worse prognosis of CRC (hazard ratio-HR, 
1.51; 95% CI, 1.01-2.27), while polymorphisms in XRCC1 Arg399Gln (HR, 0.38; 
95% CI, 0.17-0.85), XRCC3 Thr141Met (HR, 0.66; 95% CI, 0.45-0.97), and MGMT 
Leu84Phe (HR, 0.14; 95% CI, 0.02-0.99) were significantly associated with better 
prognosis. These associations were stronger among patients receiving adjuvant 
chemotherapy (Moreno et al. 2006). 
Gordon et al. (2006) selected 21 polymorphisms in 18 genes relevant to CRC (cell 
cycle regulation, drug metabolism, tumor microenvironment and ERCC1, XRCC3, 
APE1 and RAD51 genes for DNA repair) and investigated the risk of tumor 
recurrence in a total of 90 patients treated with chemotherapy (5-FU) combined with 
radiotherapy (pelvic radiation). None of the investigated DNA repair 
polymorphisms affected the risk of recurrence, while a polymorphism in IL8, an 
inflammatory cytokine with angiogenic potential, seemed to modulate recurrence 
significantly.  
Although the studies and the outcomes are still scarce, it is becoming more and 
more evident that the ultimate goal of a therapy should be to use those anticancer 
drugs that are based on the profile of a particular patient’s tumor, in order to 
maximize the potential response to therapy (Lenz, 2003). 
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1.7 Cell cycle genes  
 
The cell cycle comprises a series of tightly controlled events that drive the 
replication of DNA and cell division. It is divided into several phases: preparation 
for (G1 phase), and execution of, DNA synthesis (S phase), a second gap phase 
(G2), and mitosis (M). Quiescence (G0) is a biochemically distinct state from which 
cells can re-enter the cell cycle and go on to DNA replication and mitosis. The 
transitions between these phases are regulated by changes in the activity of specific 
cyclin-dependent kinases (CDKs), with Cdk1/Cdk2 and Cdk2/Cdk4/Cdk6 
controlling the transitions from G2 to mitosis and G1 to S phase, respectively. CDK 
proteins generally remain at constant levels throughout the cell cycle, while binding 
partners (such as cyclins) and post-translational modifiers (including kinases and 
phosphatases) undergo periodic fluctuations to regulate DNA synthesis and cell 
division. The sequential accumulation of different cyclins allows the formation of 
specific cyclin–CDK complexes that target substrates involved in transitions 
between the cell cycle phases (Caldon et al, 2006; Figure 10).  
Deregulation of cell cycle and cell proliferation mechanisms have an important role 
in carcinogenesis. A number of cell cycle genes, such as cyclins, CDKs, and the 
regulators of the CDKs, are found frequently mutated in many types of cancer. In 
addition, germ-line mutations in several cell cycle control genes, such as RB1, 3; 
BRCA1 and BRCA2, 4; TP53, 5; NF2, 6, and CHEK27 have been found to cause 
strong genetic predisposition to cancer in individuals. Although control of the G2/M 
transition is implicated in events in cancer resulting in chromosomal aberrations, the 
G1/S transition encompasses many of the important cell cycle events that may be 
specifically altered in CRC, including the actions of the oncogenes/tumor 
suppressors cyclin E, cyclin D1, and p27 (Caldon et al, 2006).  
In particular, abnormal expression of regulatory proteins that control G1/S phase 
transition, a critical rate-limiting step in cell cycle progression, are frequently 
observed. G1/S transition requires phosphorylation of the retinoblastoma protein 
(pRb), which results in the release of the E2F family of transcription factors that in 
turn activate genes essential for entry into S phase. Phosphorylation of pRb is 
initiated by cyclin D1/(CDK)4-6 complexes and completed by cyclin E/CDK2 in 
late G1. Alterations in cyclins and/or CDKs expression result in increased cell 
proliferation and are thought to contribute to malignancy. Furthermore, down-
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regulation or inactivation of the CDK inhibitors, including p21Waf1/Cip1, p27Kip1, 
and p16Ink4a, which normally cause G1 arrest by binding to cyclin-CDK 
complexes, are often observed in diverse human tumors, further rendering the cell 
susceptible to uncontrolled extracellular proliferation signals. Frequently mutated in 
a wide range of human cancers, p53 is a negative regulator of cell cycle control, 
which inhibits cell cycle progression in part by activating p21Waf1/Cip1 expression, 
and also controls the exit of cells from the cell cycle into programmed cell death 
(Bali et al, 2004). 
 
 
 
Figure 10 Simplified schema of DNA damaged induced cell cycle control (Modified from Caldon et 
al, 2006) 
 
TP53 
TP53 represents one of the most studied tumor suppressor genes in biology. Its 
product, the p53 protein, is referred to as ‘the guardian of the genome’, and 
represents a key regulator of cellular growth control (Pietsch et al 2006). p53 is a 53 
kDa phosphoprotein, encoded by 393 amino acids forming five highly conserved 
regions and four functional domains (Harris and Hollstein, 1993). In response to a 
variety of stress signals, (including genotoxic stress, and oncogene activation) the 
p53 protein is post-translationally stabilized, leading to its activation as a sequence-
specific transcription factor. This stabilization can then lead to different programs, 
depending on the cell of origin or cellular context. These include cell cycle arrest, 
senescence, or apoptosis (Jin and Levine, 2001). As a tumor suppressor, p53 is 
essential for preventing inappropriate cell proliferation and maintaining genome 
integrity in relation to genotoxic stress. Following various intracellular and 
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extracellular stimuli, such as DNA damage (induced by ionizing radiation, UV 
radiation, application of cytotoxic drugs or chemotherapeutic agents, and infectious 
virus), heat shock, hypoxia, and oncogene overexpression, wild type p53 is activated 
and emerges as a pivotal regulatory protein which triggers diverse biological 
responses, both at the level of a single cell as well as in the whole organism. p53 
activation involves an increase in overall p53 protein level as well as qualitative 
changes in the protein through extensive post-translational modification, thus 
resulting in activation of p53-targeted genes. For example, in response to DSBs in 
DNA damage, ATM protein kinase is activated which in turn activates Chk2 kinase. 
Both ATM and Chk2 then both phosphorylate p53 at distinct sites leading to p53-
dependent cell cycle arrest or apoptosis (Bai and Zhu, 2006). 
Among various cellular responses induced by p53, most notable are the induction of 
cell cycle arrest and apoptosis. It appears that the ability of p53 to prevent cell 
growth is pivotal to its tumor suppressor functions. p53 can induce cell cycle arrest 
in the G1, G2 and S phases of the cell cycle. The induction of cell cycle arrest at G1 
and G2 by p53 provides additional time for the cell to repair genomic damage before 
entering the critical stages of DNA synthesis and mitosis. The arrested cells can be 
released back into the proliferating pool through p53’s biochemical functions that 
facilitate DNA repair including NER and BER (See Figure 11, Bai and Zhu, 2006). 
 
 
 
Figure 11 p53’s biochemical functions may facilitate DNA repair including NER and BER pathways 
(Modified from Bai and Zhu, 2006). 
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p53 is well-known as the most frequently mutated gene (in more than 50% of human 
tumors) in human cancer. Some of these mutations have already been correlated to 
specific clinical phenotypes. It is therefore conceivable that the existence of natural 
variants of p53 could be linked with the development of specific diseases, owing to 
differences in the activity of variant proteins in this pathway, and could then 
represent an interesting predictive marker for preventive and early intervention 
strategies. The natural genetic variants of p53 have thus emerged as a resource to be 
studied in the understanding of inter-individual differences in cancer risk and 
therapy. 
Several polymorphisms have been identified in the TP53 gene (Olivier et al., 2002). 
Most of these polymorphisms are SNPs affecting a single base. A great number of 
these natural variants are localized in non-coding regions of the gene (introns). 
Among the polymorphisms found in the coding regions (exons) of TP53, only two 
alter the amino-acid sequence of its product, proline (Pro) to serine (Ser) at residue 
47, and arginine (Arg) to proline (Pro) at residue 72.  
 
The codon 72 polymorphism (TP53 Arg72Pro) 
This common SNP results in a non-conservative change of an Arg to a Pro at amino 
acid 72 that results in a structural change of the protein giving rise to variants of 
distinct electrophoretic mobility (Harris et al., 1986; Matlashewski et al., 1987). 
This polymorphism occurs in a proline-rich region of p53, which is known to be 
important for the growth suppression and apoptotic functions of this protein (Walker 
and Levine, 1996; Sakamuro et al., 1997). Beckman and co-workers (1994) 
demonstrate that the frequency of the Pro72 allele differs with latitude, increasing in 
a linear manner as populations near the equator. These observations led the authors 
to suggest that the codon 72 variants differed in biological activity, and further that 
these differences in activity might be subject to selection in areas of high ultraviolet 
light exposure. 
The Arg72 and Pro72 isoforms of p53 differ from the biochemical and biological 
point of view. Arg72 variant of p53, when in cis with certain tumor-derived 
mutations, might have enhanced tumor suppressive function owing to increased 
ability to inactivate p73 (the p53-homolog). Subsequent studies suggest that the 
ability of Arg72 to target and inhibit p73 may be cell-type dependent (Vikhanskaya 
et al., 2005). Specifically, these authors demonstrated that some of the p53 tumor 
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derived mutants that are unable to bind and inhibit p73, are still able to confer 
resistance to drug treatment. This result may suggest that Arg72-containing mutants 
may possess other mechanisms to disrupt chemotherapy-induced apoptosis. 
In non-mutated forms of p53, the Arg72 variant has a significantly increased ability 
to induce programmed cell death, in cells containing inducible versions of p53, as 
well as in cells homozygous for Arg72 and Pro72 (Bonafe et al., 2002; Dumont et 
al., 2003).  
In summary, the combined data from several groups has confirmed the altered 
apoptotic potential of the codon 72 polymorphic variants, with the Arg72 variant 
demonstrating enhanced apoptotic ability, and the Pro72 variant demonstrating 
enhanced growth arrest (Pim and Banks, 2004). Based on these findings, a number 
of studies have tried to establish a correlation between the TP53 Arg72Pro 
polymorphism and the risk to develop certain types of cancer. In general, these 
studies have not yielded consistent results. This may be accounted for by the fact 
that the Arg72 allele, when found in mutant forms of p53, might be predicted to 
enhance tumor development (increased inactivation of p73). However, when found 
in the context of wild-type p53, it might be predicted to better inhibit tumor 
development (increased apoptotic ability). 
 
The IARC TP53 Mutation Database (www.iarc.fr/P53/) lists 15 common 
polymorphisms in the non-coding region of TP53. Some of these natural variations 
have also been associated with increased risk of cancer development, although in the 
absence of clear indications that such variants alter the function of p53, it remains 
possible that these findings are the result of linkage to other, functionally significant, 
polymorphisms of p53.  
 
Polymorphism of intron 3 (PIN3) 
Among all of the polymorphisms identified in the TP53 gene, the polymorphism in 
intron 3 (PIN3, A1 allele is the wildtype and allele A2 is referred to a 16 bp 
duplication) has also been frequently studied. However, only a single work has 
demonstrated an altered activity of this natural variant. Harboring the assumption 
that the PIN3 A2 variant allele might influence alternative splicing of p53, 
Gemignani et al. (2004) instead reported a reduced amount of steadystate RNA for 
this allele in immortalized lymphoblastoid cell lines, relative to wild type. These 
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results were re-capitulated with mRNA extracted directly from patient lymphocytes. 
Other investigators have reported that the A2 variant allele is associated with 
decreased apoptotic and DNA repair capacity in lymphoblastoid cell lines (Wu et 
al., 2002). Consistent with these altered functional activities, several studies have 
correlated the intron 3 duplication with an increased risk of various cancers, 
including cancer of the colon (Gemignani et al., 2004), lung (Wu et al., 2002), breast 
(Weston and Godbold, 1997; Wang-Gohrke et al., 1999; Powell et al., 2002), and 
ovary (Runnebaum et al., 1995; Wang- Gohrke et al., 1999). However, other groups 
have failed to confirm these results (Khaliq et al., 2000; Mitra et al., 2005). Analysis 
of haplotypes remains a much more powerful approach than single polymorphism 
investigations, since the integration of an increasing number of common genetic 
variations in the analysis should implement an increased statistical power in such 
studies. 
 
Functionally significant polymorphisms in the p53 pathway exist which may impair 
the function of this pathway. In some cases, these variants are clearly associated 
with altered age of onset of cancer and its prognosis. However, whether these 
variants are associated with altered cancer risk is not currently clear. Such 
associations await combined analyses of multiple variants in this pathway, along 
with more precise functional studies.  
Cyclin D1 (CCND1)  
Cyclin D1 gene (also known as CCND1) is involved both in normal regulation of the 
cell cycle and in neoplasia, where it is frequently overexpressed. CCND1 plays an 
important role in the transition from the G1 phase to the S phase of the cell cycle. 
Amplification or overexpression of the CCND1 gene is common in a variety of 
cancers, and induces proliferation (Ahmed, 2006). CCND1 harbors the capacity to 
modulate cell cycle progression. A wealth of studies systematically defined the 
manner in which CCND1 functions to regulate cell cycle and oncogenic 
transformation in mammalian cells. The CCND1 locus is known to be amplified in 
specific tumor types and it is thought that this event determines a net increase in the 
proto-oncogenic functions of the cyclin D1 protein (Knudsen et al., 2006).  
CCND1 expression is highly regulated, as would be expected based on its powerful 
role in proliferative control. Its expression is induced as a delayed early response to 
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many mitogenic signals, and is universally associated with the transition from 
quiescence into the proliferative cycle (reviewed by Knudsen et al., 2006). Among 
the cyclins that regulate G1 progression, it is hypothesized that stimulation of 
CCND1 expression represents the point at which mitogenic signal transduction 
cascades are integrated to mediate engagement of the cell cycle machinery (Figure 
10). 
After induction, both CCND1 mRNA and protein levels are under stringent 
regulation. First, CCND1 mRNA levels are dramatically increased following 
mitogenic stimulation. Additionally, many oncogenes (e.g. Ras and b-catenin) 
harbor the capacity to induce CCND1 promoter activity (Tetsu and McCormick, 
1999). Once produced, the CCND1 protein is intrinsically unstable, thus providing 
an additional level of regulation. Cell cycle progression reflects the induction of a 
threshold of CCND1 protein, which is determined by the rate of expression versus 
destruction. Lastly, CCND1 is marked for degradation after genomic insult (Agami 
and Bernards, 2000), thus preventing cell cycle progression in the presence of DNA 
damage. Combined, these mechanisms contribute to the accumulation of CCND1 
protein and are believed to be critical for ensuring the progression into the cell cycle 
is restricted to the appropriate mitogenic context. 
 
Over 100 single nucleotide polymorphisms have been identified spanning the 
CCND1 locus and catalogued in public single nucleotide polymorphism databases 
(dbSNP: www.ncbi.nlm.nih.gov/SNP/; HapMap: www.hapmap.org; or GeneSNPs: 
www.genome.utah.edu/genesnps/). Of the polymorphisms identified, the CCND1 
G/A870 polymorphism has received the most investigation. The polymorphism 
frequency in the Caucasian population is approximately 44% A and 56% G, 
depending on the study (Simpson et al., 2001; Sanyal et al., 2004), but large 
variances between racial and ethnic groups have been reported. Owing to the 
significance of CCND1 in human cancer, a large number of epidemiological studies 
have challenged the influence of this particular polymorphism in cancer 
susceptibility and disease outcome. These studies generally compare the allelic 
frequency of G/A870 in disease affected or unaffected individuals, and assess 
correlations with clinical parameters (e.g. stage at diagnosis or overall survival).  
The majority of studies link the A-allele to increased cancer risk and poor disease 
outcome, with the largest associations observed with the A/A genotype. In these 
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studies, relative risks were significant but typically modest, with many studies 
reporting less than a two-fold effect. Such a result is in part to be expected for a 
common allele (i.e. A-870) that contributes to a complex phenotype. However, 
results have been inconsistent and some studies have implicated the G-allele with 
increased cancer risk, and others have ascribed no significant value to any allele of 
the G/A870 polymorphism. Combined, these results indicate that individual alleles 
may harbor differential effects in distinct tumor types. However, even within a 
specific tumor type (e.g. CRC) there have been disparate conclusions regarding the 
significance of the polymorphism. These disparities could be reflective of the patient 
population under study and the possible involvement of external factors (e.g. 
smoking or obesity) that have been suggested to cooperate with the polymorphism 
in specific studies (Buch et al., 2005; Shu et al., 2005). Important issues that remain 
to be resolved are whether the G/A870 polymorphism is the specific causal variant 
and whether there are other polymorphisms at this locus that are biologically 
relevant. It is formally possible that G/A870 is a proxy that is in linkage 
disequilibrium with the actual functional variant that is modulating cancer risk. Such 
a possibility may in part explain some of the discrepancies associated with the role 
of G/A870 in cancer in different study populations and emphasizes the importance 
of conducting linkage disequilibrium or haplotype-based investigations of common 
genetic variation across the entire locus. One group has coordinately analysed both 
the G/A870 and the G/C1722 polymorphism of CCND1 (Holley et al., 2001). This 
study indicated that the two polymorphisms are in linkage disequilibrium, such that 
individuals harboring the A870-allele are most likely also carrying the C1722-allele. 
In spite of this observation, each polymorphism had a distinct influence on disease 
(Holley et al., 2001), suggesting that other variants in addition to the G/A870 variant 
in CCND1 may be important. Therefore, although more exhaustive studies will be 
required to conclusively determine the involvement of the G/A870 polymorphism in 
cancer, there is significant evidence that it alters risk, thus necessitating study of the 
functional significance of the polymorphism (reviewed by Knudsen et al, 2006). 
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1.8 Cell cycle gene poymorphisms and susceptibility to CRC  
 
The TP53 gene plays a fundamental role in preventing the replication of damaged 
DNA (Sengupta and Harris, 2005). Somatic mutations in the TP53 gene have been 
found in many tumor types, including CRC (Ilyas and Tomlinson, 1996). Three 
different TP53 polymorphisms (i.e., in intron 3 and 6, and Arg72Pro polymorphism 
in exon 4) have been studied in sporadic CRC patients. The Arg72Pro 
polymorphism appears to be functionally relevant because the wild type allele (Arg) 
has a weaker affinity for several transcription-activating factors in vitro (Thomas et 
al., 1999). TP53 Arg72Pro is also the most frequently investigated polymorphism in 
association studies on CRC risk, although over all, inconsistent results have been so 
far obtained (Olschwang et al., 1991, Kawajiri et al., 1993, Sjalander et al., 1995, 
Gemignani et al., 2004). Two studies (Kawajiri et al., 1993, Gemignani et al., 2004) 
have suggested an increased risk associated with the Pro carrier genotypes, while in 
other studies the same genotypes have been associated with a null or statistically 
nonsignificant inverse association. Recently, Koushik et al., (2006) have found an 
association of Arg72Pro polymorphisms with increased risk of adenoma, but not 
with risk of CRC, except for women. This suggests that this polymorphism may 
play a role in the early stages of colorectal neoplasia and possibly in progression to 
invasive disease, depending on site and sex. Although the functional significance of 
the other two polymorphisms is unclear, intronic sequences in TP53 have been 
implicated in the regulation of gene expression and in DNA protein interactions 
(Avigad et al., 1997). Interesting associations have been found for the PIN3 
polymorphism: carriers for variant allele (both heterozygous and homozygous) 
showed a decreased CRC risk (Sjalander et al., 1995, Gemignani et al., 2004). 
CCND1 is also a key cell cycle regulatory protein, the expression and subcellular 
localization of which is often altered in human tumor cells. A common A/G single 
nucleotide polymorphism (G/A870) in exon 4 of the CCND1 gene is associated with 
the presence of 2 distinct mRNA transcripts for this G1/S regulatory protein (Sawa 
et al., 1998). This polymorphism could act both as a modifier of phenotypic 
expression in inherited CRC and as a low-risk susceptibility factor in sporadic 
cancer. Although still no clear and unambiguous conclusions can be drawn so far, 
several studies have observed an association between A variant of this 
polymorphism and an increased risk of both adenomas (Lewis et al., 2003) and CRC 
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(Kong et al., 2001, Porter et al., 2002, Le Marchand et al., 2003, Jiang et al., 2006), 
although in different ethnic groups. On the contrary, three studies did not find any 
association (Grieu et al., 2003, Schernhammer et al., 2006, Probs-Hensch et al., 
2006), and one observed an inverse association with the G allele (Hong et al., 
2005b).  
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2. Aim of the study 
 
The aim of the present work is to investigate the associations between the risk of 
CRC and 1) polymorphisms in genes involved in main DNA repair pathways (NER, 
BER, and DSB), 2) polymorphisms in the cell cycle control genes (CCND1, TP53) 
in a hospital-based case-control study. Potential interactions between studied 
polymorphisms and most important confounders (such as age and smoking) are also 
investigated. 532 CRC cases and 532 age- and sex-matched controls have been 
selected from a large cohort collected in the Czech Republic in the last four years. 
Rationale for the topic of PhD Thesis is based on following assumptions: A) CRC 
represents a serious health problem in the Czech Republic, as the incidence ranks 
the third highest worldwide and the incidence of rectal cancer is the highest. PhD 
Thesis is a part of an extensive project aimed at the evaluation of genetic factors 
involved in the onset of CRC. B) DNA repair gene polymorphisms were selected, 
assuming that environmental/life style factors play important role in the sporadic 
CRC risk, probably due to the accumulation of DNA damage over years. The 
relationship between the DNA repair genotypes (in particular for base excision 
repair) and the functional outcome recently investigated the cancer-free population 
from the same region has provided the necessary background for the selection of the 
investigated SNPs. Additionally, our previous work revealed an association between 
chromosomal damage and polymorphisms in NER genes. C) The close link between 
DNA repair pathways and cell cycle control inspired us to address SNPs in genes 
involved in double-strand break repair and cell cycle control (e.g. NBS1-TP53). The 
experimental work of the present PhD Thesis was performed in the Department of 
Molecular Biology of Cancer (Institute of Experimental Medicine, Academy of 
Science of the Czech Republic, Prague). 
The PhD Thesis presents the results on the association between CRC risk and 
selected polymorphisms in DNA repair genes (XPD Lys751Gln, XPG Asn1104His, 
XPC Lys939Gln, XRCC1, Arg194Trp and Arg399Gln, hOGG1 Ser326Cys, APE1 
Asn148Glu, XRCC3 Thr241Met and NBS1 Glu185Gln) and in cell cycle control 
genes (CCND1 G/A870, TP53 PIN3 and Arg72Pro).  
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3. Material and methods 
 
3.1 Study population  
 
For the present hospital-based case–control study six oncological and five large 
gastroenterological departments all over the Czech Republic contributed by 
providing blood samples and anamnestical data. The study is based on incident 
cases, the recruitment of which started in September 2004 and finished in February 
2006.  
Cases consist of patients with positive colonoscopic results for malignancy, 
histologically confirmed as colon or rectal carcinomas. Controls were defined as 
subjects undergoing colonoscopy for various gastrointestinal complaints and 
sampled at the same time as cases, whose colonoscopic results were negative for 
malignancy or idiopathic bowel diseases. 
Study subjects provided the information on their lifestyle habits (smoking, drinking, 
diet etc.), tentative occupational exposure to xenobiotics, and family/personal 
history of cancer, with the use of structured questionnaires.  
Blood samples were collected from 884 CRC patients and 598 controls. 
Subsequently, 532 case control pairs were created, matching strictly for age and sex.  
The genetic analyses did not interfere with diagnostic or therapeutic procedures for 
the subjects. DNA was isolated from coded blood samples and stored at –80°C. 
All participants signed an informed written consent and the design of the study was 
approved by the Ethical Committee of the Institute of Experimental Medicine, 
Prague, Czech Republic. 
 
3.2 Genotypes analyses 
 
DNA repair genotyping 
SNPs in genes encoding various DNA repair enzymes were determined by PCR-
RFLP or by Real-Time PCR allelic discrimination assay. For XPD Lys751Gln, XPG 
Asn1104His, XPC Lys939Gln, XRCC1, Arg194Trp and Arg399Gln, hOGG1 
Ser326Cys, XRCC3 Thr241Met, the PCR was carried out using primers and 
conditions given in Vodicka et al (2004, 2006). The amplified fragments were 
digested with appropriate restriction endonucleases and the digested PCR products 
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were resolved on 2% agarose gel and visualized under UV light after staining with 
ethidium bromide. Genetic polymorphisms in APE1 Asn148Glu and NBS1 
Glu185Gln were analysed using the TaqMan allelic discrimination assay (Applied 
Biosystems, Assay-on-demand, SNP Genotyping products: C_26470398_10 for 
NBS1 and C_8921503_10 for APE1). The TaqMan genotyping reaction was 
amplified on a 7500 Real-Time PCR system (95°C for 10 min, 92°C for 15 sec, and 
60°C for 1 min for 40 cycles). 
 
Cell cycle genes genotyping 
SNPs in genes encoding cell-cycle control enzymes were determined by PCR-
RFLPanalysis. For TP53 PIN3 polymorphism the PCR was carried out using 
primers and conditions given in Gemignani et al (2004). The167 bp CCND1 
G/A870 PCR products were amplified with the primers 5´-
GTGTAAGTTCATTTCCAATCCGC-3´(sense) and 5´-
TAAGTGAGGGTGATGTCCC-3´(antisense) and digested with MspI. The G allele 
revealed 145 and 22 bp fragments following digestion and 2% agarose gel 
electrophoresis, whilst the A allele was not digested by MspI. The 199 bp TP53 
Arg72Pro PCR products were amplified with the primers 5´-
TTGCCGTCCCAAGCAATGGATGA-3´(sense) and 5´-
TCTGGGAAGGGACAGAAGATGAC-3´(antisense) and digested with BstUI. The 
Arg allele revealed 113 and 86 bp fragments following digestion and 2% agarose gel 
electrophoresis, whilst the Pro allele was not digested by BstUI. 
All of the PCR reactions were carried out by a Peltier Thermal Cycler (PTC 200), 
MJ Research, in a final volume of 20ul containing 100ng of each primer, 50ng 
genomic DNA, 3mM MgCl2, 0,5ul dNTPs (2mM) and 1 U of HotFireTaqPolimerase 
(Odex, Italy) in the buffer provided by the manufacturer. 
 
The genotype screening was performed simultaneously for cases and controls. The 
results were regularly confirmed by random re-genotyping of more than 10% of the 
samples for each polymorphism analysed. 
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3.3 Statistical analyses 
 
Genotype distribution for each polymorphism was tested in controls for Hardy-
Weinberg equilibrium and differences in expected and observed frequencies were 
tested for statistical significance by Pearson chi-square test. Differences in baseline 
sociodemographic characteristics between cases and controls were analyzed using 
chi-square test and Student’s t-test. Multivariate logistic regressions were used to 
examine the association between each genotype and risk of selected health 
endpoints (all CRC, colon cancer, and rectal cancer separately). Odds ratio (OR) and 
95% confidence interval (CI) were estimated with matching factors (age, gender) 
and potential confounders (smoking) included in the models. Combinations of 
genotypes, selected from SNPs in genes of the same DNA repair pathway, were 
constructed and investigated for their possible impact on CRC risk. The size of the 
cohort enabled investigations of binary combinations only. Furthermore, stratified 
analyses were conducted to evaluate effects of potentially modifying factors such as 
age (the age groups based on tertiles of age distribution) and smoking status 
(smokers vs. non-smokers) on the associations of interest. All tests were two-sided 
and performed on 5% level of statistical significance. Statistical calculations were 
performed using SPSS 13.0 for Windows (Chicago, Il, USA). 
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4. Results 
 
4.1 Studied population 
The main characteristics of the subjects involved in the study are reported in Table 
1. 
The age range of individuals from the cohort was between 26-86 years old with a 
fairly similar mean age at the diagnosis for both CRC cases and controls (57.4±12.8 
and 58.5±10.5 years, respectively). The stratification for the cancer site revealed a 
prevalence of patients with colon cancer (n=335) in comparison with patients with 
rectal cancer (n=197). However, the age range and the mean age at the diagnosis 
were similar in both subgroups. Based on the information collected in the 
questionnaires concerning the lifestyle habits, the smoking habit was the only 
confounder analyzed in this study. Smokers were considered individuals currently 
smoking at the time of the diagnosis or individuals who had quit smoking in the last 
5 years from the moment of the diagnosis. The distribution of smokers/non-smokers 
was not different between the cases and controls, with a majority of individuals 
belonging to the category non-smokers (71.7% and 73.2% resp.). Other lifestyle 
factors were not included into the present exploratory study since they were either 
based on a limited number of observations or their reliability needed to be proven 
Therefore this information was not suitable for statistical analyses at the moment of 
compiling the present work. 
 
4.2 Polymorphisms in DNA repair genes  
Allelic frequencies for DNA repair gene polymorphisms are presented in Table 2, 
and are in agreement with previous reports on the central European population 
(Vodicka et al, 2004, 2006). 
None of the studied polymorphisms was independently associated with CRC risk in 
either codominant (considering together individuals bearing at least one variant 
allele) or dominant (separating individuals with heterozygous and homozygous 
variant genotypes) model of inheritance (Table 2). An association of borderline 
significance (p=0.06) was observed for APE1 Asn148Glu polymorphism. 
Individuals homozygous for the variant allele of the polymorphism exhibited a 
moderately increased risk of CRC (OR: 1.39, 95% CI 0.98-1.96). 
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When analyzing a specific cancer site (Table 3), the variant allele homozygous 
genotype for the APE1 Asn148Glu polymorphism was associated with an increased 
risk of colon cancer (OR: 1.50, 95% CI 1.01-2.22; p=0.05). On the contrary, 
individuals bearing homozygous variant allele genotype for the Glu185Gln 
polymorphism in the NBS1 gene exhibited a moderately decreased risk of colon 
cancer (OR: 0.65, 95% CI 0.40-1.04; p=0.07). When similar analyses were 
performed on patients with rectal cancer, no independent association with either 
polymorphism emerged (Table 3).  
 
Genotype combination interactions 
Binary genotype combination interactions were tested for association with CRC risk 
for selected SNPs in genes involved in the same DNA repair pathway. We found a 
significantly increased risk of CRC in individuals carrying variant allele 
homozygous genotypes for both APE1 Asn148Glu and hOGG1 Ser326Cys 
polymorphisms (OR: 6.37, 95% CI 1.40-29.02; p=0.02, Table 4). The same 
genotype combination also showed an increased risk for colon cancer (OR: 7.14, 
95% CI 1.49-34.38; p=0.01, Table 5). Analysis for rectal cancer suggests that 
individuals bearing XPD 751GlnGln and XPG 110HisHis genotypes in combination 
may exhibit increased risk for this particular cancer (OR: 8.14, 95% CI 0.87-86.36; 
p=0.06), but there were only three individuals in the cases and one person in 
controls. This is likely due to the fact that rectal cancer group accounted for 197 
individuals.  
 
Interaction of genotypes and smoking habit 
The modifying effect of smoking habit on association between DNA repair 
polymorphisms and CRC risk was evaluated by applying multivariate analyses, 
obtained for strata of smokers and non-smokers. A significant interaction was 
observed between smoking habits and the hOGG1 Ser326Cys polymorphism. 
Smokers with variant allele homozygous genotype for the polymorphism showed an 
increased risk of CRC (OR: 4.17, 95% CI 1.17-15.54; p=0.03). 
The modifying effect of smoking in the association between selected combinations 
of genotypes and CRC risk was evaluated in analoguous way as above. Smokers 
carrying variant allele homozygous genotype for the XPC Lys939Gln and 
heterozygous genotype for the XPG Asn1104His showed an increased risk of CRC 
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(OR: 5.95, 95% CI 1.27-29.14; p=0.03). Smoking patients carrying the XPC variant 
allele homozygous genotype and XPD heterozygous genotype combination 
exhibited an increased risk for colon cancer risk as compared to corresponding 
smoking controls (OR: 8.22, 95% CI 1.50-45.30; p=0.01). 
 
Interaction with age 
Cases and controls were stratified into three age groups of fairly similar size (tertiles 
of age distribution: 26-54 years, 55-63 years, and 64-86 years) to assess an influence 
of this variable. The association of APE1 Asn148Glu polymorphism with increased 
CRC risk became more pronounced after the stratification for age. Both 
heterozygous and homozygous genotypes exhibited significantly increased risk of 
CRC (OR: 1.79, 95% CI 1.04-3.07; p=0.04, OR: 2.57, 95% CI 1.30-5.06; p=0.007, 
respectively) in the age group of 64-86 years. This association was particularly 
evident for colon cancer (OR: 1.86, 95% CI 0.99-3.50; p=0.05 for heterozygous 
genotype and OR: 3.02, 95% CI 1.41-6.49; p=0.005 for homozygous genotype). An 
association of borderline significance was observed also for hOGG1 Ser326Cys 
variant genotype in the oldest group and both CRC (OR: 7.17, 95% CI 0.86-59.7; 
p=0.07) and colon cancer risk (OR: 8.19, 95% CI 0.96-70.14; p=0.06). Association 
with rectal cancer risk was recorded for XPG Asn1104His variant allele in the group 
of oldest (64-86 years) individuals with heterozygous (OR: 1.94, 95% CI 0.95-3.97; 
p=0.07) and homozygous (OR: 9.52, 95% CI 1.59-57.02; p=0.01) genotype.  
 
4.3 Polymorphisms in cell cycle control genes 
Allelic frequencies for cell cycle gene polymorphisms are presented in Table 6, and 
are determined for the particular population for the first time. None of the studied 
polymorphisms was independently associated with CRC risk in either codominant 
(considering together individuals bearing at least one variant allele) or dominant 
(separating individuals with heterozygous and homozygous variant genotypes) 
model of inheritance. 
The stratification for the specific cancer site did not reveal any association of the 
selected polymorphisms with risk of colon or rectal cancer (Table 7). 
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Genotype combination interactions 
We tested genotype combination interactions for association with CRC risk for 
SNPs in the selected genes involved in cell cycle control pathway. None of the 
analysed combinations was associated with an altered CRC risk. However, after 
stratification for cancer site, we found a significant association with increased risk 
of colon cancer in individuals carrying at least two variant alleles for both TP53 
PIN3 and TP53 Arg72Pro polymorphisms (OR: 2.61, 95% CI 1.78-3.84; p≤0.0001, 
Table 8). 
Due to a tight link between DNA repair and TP53 genes, we analysed a possible 
interaction between APE1 Asn148Glu and TP53 PIN3 and Arg72Pro 
polymorphisms, respectively. No significant interaction was found for these 
combinations. 
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Table 1. Selected characteristics of CRC cases and healthy controls 
 Controls 
(n=532) 
All cases 
(n=532) 
Colon cancer 
(n=335) 
Rectal cancer 
(n=197) 
Gender     
Males 294 294 167 127 
Females 238 238 168 70 
     
Age at diagnosis 
(years) 
    
Mean±SD 57.4±12.8 58.5±10.5 58.5±10.9 58.4±9.7 
Range 29-85 26-86 26-84 26-86 
     
Smoking status     
Non-smokers 71.7% (358) 73.2% (372) 75.6% (242) 69.1% (130) 
Smokers 28.3% (141) 26.8% (136) 24.4% (78) 30.9% (58) 
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Table 2 Distribution of DNA repair polymorphisms and risk of CRC 
Genotypes Controls 
(n=532)) 
Cases 
(n=532) 
OR (95% CI) P value 
Base-excision repair     
XRCC1 Arg194Trp     
ArgArg 466 454 1.00  
ArgTrp 59 72 1.24 (0.86-1.80) 0.25 
TrpTrp 5 6 1.17 (0.35-3.87) 0.80 
ArgTrp+TrpTrp 64 78 1.24 (0.87-1.77) 0.24 
XRCC1 Arg399Gln     
ArgArg 219 229 1.00  
ArgGln 240 233 0.93 (0.72-1.21) 0.60 
GlnGln 73 68 0.88 (0.60-1.29) 0.52 
ArgGln+GlnGln 313 301 0.92 (0.72-1.18) 0.51 
hOGG1 Ser326Cys     
SerSer 331 336 1.00  
SerCys 181 168 0.91 (0.70-1.18) 0.47 
CysCys 20 28 1.43 (0.79-2.59) 0.24 
SerCys+ CysCys 201 196 0.96 (0.75-1.23) 0.74 
APE1 Asn148Glu     
AsnAsn 157 140 1.00  
AsnGlu 267 261 1.10 (0.83-1.47) 0.50 
GluGlu 106 130 1.39 (0.98-1.96) 0.06 
AsnGlu+GluGlu 373 391 1.18 (0.91-1.55) 0.22 
Nucleotide-excision repair     
XPD Lys751Gln     
LysLys 174 189 1.00  
LysGln 264 258 0.89 (0.68-1.17) 0.41 
GlnGln 94 85 0.82 (0.57-1.18) 0.28 
LysGln+GlnGln 358 343 0.87 (0.68-1.13) 0.30 
XPG Asn1104His     
AsnAsn 356 334 1.00  
AsnHis 153 177 1.25 (0.96-1.63) 0.10 
HisHis 23 21 0.99 (0.54-1.83) 0.98 
AsnHis+HisHis 176 198 1.22 (0.94-1.57) 0.13 
XPC Lys939Gln     
LysLys 189 171 1.00  
LysGln 243 268 1.23 (0.94-1.61) 0.14 
GlnGln 100 93 1.02 (0.72-1.45) 0.90 
LysGln+GlnGln 343 361 1.17 (0.90-1.50) 0.23 
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Double-strand break repair     
XRCC3 Thr241Met     
ThrThr 219 203 1.00  
ThrMet 250 264 1.14 (0.88-1.48) 0.32 
MetMet 63 65 1.11 (0.75-1.65) 0.61 
ThrMet+MetMet 313 329 1.13 (0.89-1.45) 0.32 
NBS1 Glu185Gln     
GluGlu 239 246 1.00  
GluGln 220 234 1.03 (0.80-1.33) 0.83 
GlnGln 71 52 0.71 (0.48-1.06) 0.10 
GluGln+GlnGln 291 286 0.95 (0.75-1.21) 0.68 
a Unconditional logistic regression analysis adjusted for age and sex.
Table 3 Distribution of DNA repair polymorphisms and risk of CRC in specific sites 
Genotypes Controls (n=532) Colon (n=335) OR (95% CI) P value  Rectum (n=197) OR (95% CI)  P value 
Base-excision repair         
XRCC1 Arg194Trp         
ArgArg 466 288 1.00   166 1.00  
ArgTrp 59 45 1.24 (0.82-1.88) 0.32  27 1.24 (0.76-2.03) 0.38 
TrpTrp 5 2 0.61 (0.12-3.21) 0.56  4 1.92 (0.51-7.31) 0.34 
ArgTrp+TrpTrp 64 47 1.19 (0.79-1.78) 0.41  31 1.30 (0.82-2.07) 0.27 
XRCC1 Arg399Gln         
ArgArg 219 152 1.00   77 1.00  
ArgGln 240 146 0.87 (0.65-1.16) 0.33  89 1.09 (0.76-1.56) 0.63 
GlnGln 73 37 0.71 (0.45-1.11) 0.14  31 1.29 (0.78-2.12) 0.32 
ArgGln+GlnGln 313 183 0.83 (0.63-1.09) 0.19  120 1.14 (0.81-1.59) 0.46 
hOGG1 Ser326Cys         
SerSer 331 225 1.00   111 1.00  
SerCys 181 90 0.73 (0.53-0.98) 0.03  78 1.29 (0.91-1.81) 0.15 
CysCys 20 20 1.52 (0.80-2.91) 0.20  8 1.22 (0.52-2.86) 0.65 
SerCys+ CysCys 201 110 0.80 (0.60-1.07) 0.14  86 1.28 (0.92-1.79) 0.15 
APE1 Asn148Glu         
AsnAsn 157 82 1.00   58 1.00  
AsnGlu 267 171 1.22 (0.87-1,69) 0.25  91 0.96 (0.65-1.42) 0.85 
GluGlu 106 82 1.50 (1.01-2.22) 0.05  48 1.24 (0.79-1.96) 0.35 
AsnGlu+GluGlu 373 153 1.30 (0.95-1.77) 0.10  139 1.05 (0.73-1.50) 0.81 
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Nucleotide-excision 
repair 
        
XPD Lys751Gln         
LysLys 174 118 1.00   71 1.00  
LysGln 264 162 0.90 (0.66-1.22) 0.48  96 0.88 (0.62-1.27) 0.51 
GlnGln 94 55 0.87 (0.58-1.31) 0.51  30 0.76 (0.46-1.24) 0.27 
LysGln+GlnGln 358 217 0.89 (0.67-1.89) 0.43  126 0.85 (0.60-1.20) 0.36 
XPG Asn1104His         
AsnAsn 356 213 1.00   121 1.00  
AsnHis 153 113 1.26 (0.93-1.70) 0.13  64 1.22 (0.85-1.75) 0.27 
HisHis 23 9 0.69 (0.31-1.53) 0.36  12 1.50 (0.72-3.11) 0.28 
AsnHis+HisHis 176 122 1.19 (0.89-1.59) 0.24  76 1.26 (0.89-1.77) 0.19 
XPC Lys939Gln         
LysLys 189 105 1.00   66 1.00  
LysGln 243 176 1.30 (0.96-1.78) 0.09  92 1.11 (0.76-1.60) 0.59 
GlnGln 100 54 0.97 (0.64-1.46) 0.88  39 1.11 (0.70-1.77) 0.65 
LysGln+GlnGln 343 230 1.21 (0.90-1.61) 0.21  131 1.11 (0.78-1.57) 0.56 
Double-strand break 
repair 
        
XRCC3 Thr241Met         
ThrThr 219 133 1.00   70 1.00  
ThrMet 250 162 1.07 (0.80-1.44) 0.65  102 1.27 (0.89-1.82) 0.18 
MetMet 63 40 1.06 (0.67-1.66) 0.81  25 1.22 (0.71-2.09) 0.47 
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ThrMet+MetMet 313 202 1.07 (0.81-1.41) 0.64  127 1.26 (0.90-1.78) 0.18 
NBS1 Glu185Gln         
GluGlu 239 154 1.00   92 1.00  
GluGln 220 151 1.07 (0.80-1.43) 0.65  83 0.97 (0.68-1.38) 0.87 
GlnGln 71 30 0.65 (0.40-1.04) 0.07  22 0.80 (0.47-1.38) 0.43 
GluGln+GlnGln 291 181 0.97 (0.73-1.27) 0.81  105 0.93 (0.67-1.29) 0.67 
a Unconditional logistic regression analysis adjusted for age and sex. 
Table 4 Selected SNP-SNP interaction for CRC cancers 
APE1 Asn148Glu genotypes Cases/Controls 
OR (95% CI) 
Asn/Asn Asn/Glu Glu/Glu 
Ser/Ser 
97/92 
1 
164/169 
0.93 (0.65-1.32) 
75/69 
1.03 (0.67-1.59) 
    
Ser/Cys 
40/59 
0.64 (0.39-1.04)* 
86/86 
0.94 (0.62-1.43) 
42/35 
1.16 (0.68-1.97) 
    
hOGG1 
Ser326Cys 
genotypes 
 
Cys/Cys 
3/6 
0.50 (0.12-2.06) 
12/12 
0.99 (0.42-2.31) 
13/2 
6.37 (1.40-29.02)**
*  p=0.07 
**p=0.02 
 
 
 
Table 5 Selected SNP-SNP interaction for colon cancers 
APE1 Asn148Glu genotypes Cases/Controls OR (95% CI) 
 Asn/Asn Asn/Glu Glu/Glu 
Ser/Ser 
59/92 
1 
116/169 
1.08 (0.72-1.62) 
50/69 
1.15 (0.70-1.87) 
    
Ser/Cys 
21/59 
0.57 (0.31-1.03)* 
46/86 
0.81 (0.50-1.33) 
23/35 
1.66 (0.57-1.98) 
    
hOGG1 
Ser326Cys 
genotypes 
  
Cys/Cys 
2/6 
0.57 (0.11-2.94) 
9/12 
1.22 (0.48-3.08) 
9/2 
7.14 (1.49-34.38)**
*  p=0.06 
**p=0.01 
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Table 6 Distribution of Cell-cycle polymorphisms and risk of CRC 
Genotypes Controls 
(n=544) 
 Cases  
(n=544) 
 OR (95% CI) P value 
TP53 PIN3       
A1A1 393  380  1.00  
A1A2 143  1572  1.10 (0.84-1.44) 0.69 
A2A2 8  12  1.55 (0.63-3.84) 0.48 
A1A2+A2A2 151  164  1.12 (0.86-1.46) 0.92 
TP53 Arg72Pro       
ArgArg 285  287  1.00  
ArgPro 212  203  0.95 (0.74-1.22) 0.48 
ProPro 45  53  1.17 (0.76-1.80) 0.34 
ArgPro+ProPro 257  256  0.98 (0.78-1.26) 0.38 
CCND1 G/A870       
GG 138  138  1.00  
GA 285  263  0.92 (0.69-1.23) 0.58 
AA 119  143  1.20 (0.86-1.69) 0.29 
GA+ AA 404  406  1.01 (0.76-1.32) 1.00 
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Table 7 Distribution of cell cycle polymorphisms and risk of CRC in specific sites 
Genotypes Controls (n=544) Colon (n=341) OR (95% CI) P value Rectum (n=202) OR (95% CI)  P value 
TP53 PIN3        
A1A1 393 238 1.00  142 1.00  
A1A2 143 94 1.08 (0.79-1.47) 0.60 58 1.12 (0.78-1.61) 0.53 
A2A2 8 9 1.86 (0.71-4.88) 0.20 3 1.04 (0.27-3.97) - 
A1A2+A2A2 151 103 1.13 (0.84-1.52) 0.43 61 1.12 (0.78-1.59) 0.54 
TP53 Arg72Pro        
ArgArg 285 171 1.00  116 1.00  
ArgPro 212 137 1.08 (0.81-1.43) 0.61 66 0.76 (0.54-1.09) 0.13 
ProPro 45 32 1.19 (0.73-1.94) 0.50 21 1.15 (0.65-2.01) 0.63 
ArgPro+ProPro 257 169 1.10 (0.84-1.44) 0.51 87 0.83 (0.60-1.15) 0.27 
CCND1 G/A870        
GG 138 85 1.00  53 1.00  
GA 285 166 0.73 (0.53-0.98) 0.74 97 0.89 (0.60-1.31) 0.54 
AA 119 90 1.52 (0.80-2.91) 0.30 53 1.16 (0.74-1.82) 0.52 
GA+ AA 404 256 0.80 (0.60-1.07) 0.86 150 0.97 (0.67-1.40) 0.86 
 
Table 8 Selected SNP-SNP interaction for colon cancer 
TP53 PIN3 genotypes Cases/Controls 
OR (95% CI) 
A1/A1 A1/A2+A2/A2 
Arg/Arg 
227/84 
1 
58/14 
0.65 (0.35-1.23) TP53 Arg72Pro 
genotypes Arg/Pro+Pro/Pro 166/81 1.31 (0.92-1.90) 
91/88 
2.61 (1.78-3.84)* 
*p≤0.0001 
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5. Discussion 
 
While hereditary CRC is associated with high-penetrance mutations in several 
genes, the genetic determinants of the disease at population levels remain to be 
understood. Polymorphisms in critical genes can potentially alter the susceptibility 
to different cancers including CRC. The role of genetic variants (e.g. SNPs) in genes 
encoding key players in the susceptibility to the sporadic CRC is not satisfactorily 
clarified at present. One of the key players in CRC risk seems to be MTHFR C677T 
(Kono and Chen, 2005), along with polymorphisms in genes involved in metabolism 
and inflammatory processes. Recent years have also evidenced growing attention 
devoted to the role of DNA repair genes as CRC risk modulators. Interindividual 
variations in DNA repair genes may confer altered DNA repair capacity, and thus an 
enhanced cancer risk (Berwick ans Vineis, 2005). 
 
In this study, we tested the hypothesis, whether SNPs in the genes encoding 
different DNA repair enzymes influence the risk of CRC. A further interest was 
devoted in exploring the possible modulating role of cell cycle control gene 
polymorphisms, but the results presented in this work are still preliminary. The 
study population was drawn from the Czech Republic, a country with one of the 
highest incident rates for colorectal cancer and the highest incidence rate for rectal 
cancer (Boyle and Langman, 2000, Janout and Kollarova, 2001, Parkin et al, 2005).  
The strength of the present study is that (a) the cases and controls matched for age 
and sex, confounding factors known to introduce substantial bias in association 
studies (Wacholder et al, 2004); (b) an adequate size of the cohorts; (c) a 
representative character of the cohorts for the entire country (and, basically, for 
central Europe), a very homogeneous area, with generally typical lifestyle and 
dietary habits, in particular over the last 50-60 years; (d) several genetic 
polymorphisms, involved in relevant DNA repair and cell cycle control pathways 
assayed for simultaneously; (e) the inclusion of only colonoscopically negative 
individuals as controls; even though this selection may not necessarily represent the 
general population, but it does ensure disease-free control individuals. 
The data analysis showed that none of the DNA repair polymorphisms included in 
this study was associated with the risk modulation of CRC. However, homozygote 
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carriers of variant allele of the Asn148Glu polymorphism in the BER APE1 gene 
were at a marginally increased risk of the disease. The stratification of cases 
according cancer site pointed effect of 148Glu homozygous genotype confined to 
colon cancer. Interestingly, an observed increased risk in individuals, homozygous 
for variant alleles of the APE1 Asn148Glu and hOGG1 Ser326Cys polymorphisms, 
in both CRC and colon cancer indicated multiplicative gene-gene interaction. This 
interaction between genes involved in BER is probably suggestive of a modulating 
role for inflammatory processes/oxidative stress in colon cancer (Sanders et al., 
2004). The APE1 and hOGG1 genes are known to repair oxidative DNA damage as 
a part of BER pathway (Weiss et al, 2005) and the relationships between the 
polymorphisms of these genes and functional outcomes have recently been 
highlighted in healthy subjects. An increased number of variant alleles for both 
hOGG1 Ser326Cys and APE1 Asn148Glu was associated with a significantly 
decreased repair of DNA oxidative damage (Vodicka et al., 2006). Similar to our 
findings, the Ser326Cys polymorphism of hOGG1 was the only one (out of 12 
investigated polymorphisms in BER genes) that showed a significant association 
with an increased risk of CRC in a Spanish cohort of CRC patients (Moreno et al., 
2006). Although hOGG1 Ser326Cys is one of the most frequently analyzed BER 
polymorphisms, the outcomes remain inconclusive (Kim et al, 2003; Hansen et al, 
2005). On the other hand, there is only one report on APE1 polymorphism on the 
CRC risk, where no significant association was found (Moreno et al., 2006).  
 
In general, none of the SNPs in any of the DNA repair genes have so far been 
strongly associated with adenoma or CRC risk (Bigler et al, 2005; Stern et al, 2005; 
Moreno et al., 2006). The outcomes of different studies vary substantially, as 
recently reviewed by Naccarati et al. (2007). Our present results are in accordance 
with the observations that none of the individually analyzed DNA repair 
polymorphisms have been unambiguously associated with CRC risk so far. The 
number of total investigated genes and related polymorphisms in literature is 
extensive (almost 30 DNA repair genes for more than 70 polymorphisms). 
However, only few of them have been analysed in two and more studies and, in the 
majority of cases, a comparison of results to highlight general trends is not yet 
feasible. In general, there are no strong associations between DNA repair SNPs and 
adenoma or CRC risk, observed consistently in more investigations. Many studies 
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did not reveal any significant association at all. The majority of studies focused on 
polymorphisms in genes of BER and NER pathways, XRCC1 and XPD in particular. 
Considering the putative subtle effect of many DNA repair polymorphisms, the 
impact of individual SNPs on CRC risk is indeed expected to be low. The current 
assumption is that the onset of sporadic CRC may be triggered by multiple 
environmental/life style factors with possible interaction with genetic factors like 
polymorphisms (De la Chapelle, 2004).  
Although there is a weak association between single DNA repair polymorphisms, 
when assayed for adenoma and CRC risk, more realistic information may be 
provided by analyzing polymorphisms in combinations. Single SNPs in low-
penetrance genes are unlikely to affect the susceptibility to cancer, but an “adverse 
combination” of less favorable genetic variants can exert and amplify a negative 
effect. However, analysis of SNPs in combination reduces the number of 
observations and decreases the statistical power of the studies. Only a few studies 
addressed DNA repair gene-gene interactions so far: particular combinations of 
XPD K751Q, XRCC1 Arg399Gln and XRCC3 Thr241Met wildtype genotypes were 
associated with an increased CRC risk in a cohort of 727 CRC patients and 736 
controls from Taiwan (Yeh et al, 2005a). Investigations of more SNPs in the same 
DNA repair gene (especially for XPD, ERCC1, EXO1, and MGMT) are shown in 
Tables 1-5 of the Introduction. In this context, haplotype studies appear as more 
informative. A haplotype, a set of closely linked alleles (SNPs), is inherited as a 
unit, ultimately covering the variability within a gene (International HapMap, 2005). 
Modulating effect of haplotypes was investigated 3-times for XRCC1 combined 
polymorphisms (Arg194Trp, Arg280His and Arg399Gln). Specific XRCC1 
haplotypes increased the risk of CRC in interaction with alcohol intake (Hong et al, 
2005a), and adenoma risk in concomitance with fatty acid intake (Stern et al, 2005). 
The same haplotype was associated with a decreased CRC risk in young individuals 
only (Moreno et al, 2006).  
A critical analysis of the available association studies reveals several limitations, 
which have been possibly avoided in the present study. The most important critical 
point is associated with the often too small size of cohorts of cases and controls, 
resulting in a low statistical power and false, by chance, positive or negative 
outcomes. Several studies have showed the bias introduced by analyses performed 
in small populations (Wacholder et al, 2004). In this context, the number of studies 
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exceeding 500 cases, like the present cohort from Czech Republic, is currently still 
limited, both for colorectal adenoma and CRC (Kim et al, 2004a; Yeh et al, 2005a,b, 
and 2006). An additional important aspect concerns the inclusion (often 
disproportional) of different ethnic groups into the cases and the controls, with a 
subsequent obscuring of the outcomes. Different results may be expected due to 
intrinsic differences in the genetic background among Caucasians, Asians, African-
Americans and other ethnic groups. Only in the most recent DNA repair association 
studies were the statistical analyses for the stratification of ethnicity included (Stern 
et al, 2005; Jin et al, 2005; Berndt et al, 2006, 2007; Goodman et al 2006; Huang et 
al, 2006). 
The proper recruitment of cases and controls represents another key factor, which 
characterizes different studies. Whereas in adenoma and CRC patients we can 
follow the use of standard criteria for the diagnosis (e.g. colonoscopy, histological 
examination), a very complicated situation appears in recruited control individuals. 
The use of population-based unscreened control group does not prevent inclusion of 
individuals with undetected polyps, with subsequent attenuation of the study 
findings. The studies including only colonoscopically negative individuals may not 
be representative of the general population. They rather comprise individuals with 
any clear indication for colonoscopy, such as putative positive family history or any 
gastrointestinal problems. On the other hand, the major advantage of this clinic-
based approach is obtaining the control group free of polyps or CRC. Another 
approach is the recruitment of only cancer-free individuals as a control population 
(i.e. individuals declaring no history of cancer in the past for them and for family, 
and/or individuals tested for cancer). Since it employs directed questionnaires, the 
reliability of answers should be considered and, if possible, verified. Besides, 
various cancer tests (expensive and laborious) are not yet completely reliable. 
Optimally, the use of two independent control groups (one screened for colonoscopy 
and one constituted by healthy general population) would minimize biases. 
Proper matching cases and controls for age and sex were also rarely recorded. 
Modulating effects of age and sex on CRC onset may only be investigated by 
comparing matched cohorts. This was the main reason why we have restricted our 
cohort only to perfectly matched sex and age cases and controls. 
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The investigation of gene-environment interactions implies the simultaneous study 
of both environmental exposure and relevant genetic polymorphisms. While the 
genotyping methods are quite accurate, a reliable determination of the 
environmental exposure is both laborious and expensive (i.e. measurement of 
external/internal dose of a chemical or its metabolites) or unreliable and non-
quantitative (i.e. information based on questionnaires only). In this present study, we 
attempted to address a major environmental/life style factor, smoking, and one 
major confounder, age. However, an inclusion of other variables (planned as a 
prospect) would have decreased the statistical power, after stratification of the 
cohort. We found a significant interaction between smoking habit and the hOGG1 
Ser326Cys polymorphism. The smokers carrying 326Cys/Cys genotype showed an 
increased risk of CRC as compared to control smokers. In another association study, 
based on 772 high-risk adenomas cases and 777 controls, a particular combination 
of three linked nonsynonymous polymorphisms in XPC (Arg492His, Ala499Val, 
and Lys939Gln) increased smoking related risk for colorectal adenoma (Huang et al, 
2006). Similarly, in this present study, smoking patients carrying XPC 939GlnGln 
and XPD 751LysGln combined genotypes exhibited an increased risk for colon 
cancer risk.  
Age also seems to be a relevant factor affecting the association between APE1 
Asn148Glu polymorphism and an increased CRC risk, as the effect of above 
polymorphism was most pronounced in individuals between 64 and 86 years old. 
The XPG Asn1104His polymorphism exhibited an association with rectal cancer 
risk in the group of oldest individuals included in the study. This phenomenon is 
difficult to explain, however, as many influencing factors can cause an increased 
susceptibility during a lifetime. An unsubstantiated explanation could be differential 
accumulation of DNA damage due to different genotypes. This is likely to increase 
rather among older individuals as well as consequences of time, or as an exhaustion 
of compensatory repair efficiency in the case of adverse genotype in one or two 
repair genes with functional impact. Similarly, Jin et al (2005), found that XRCC3 
241Met allele was associated with CRC risk among older individuals (>60 years). 
On the other hand, several studies reported an increased susceptibility to adenoma or 
CRC risk in younger individuals (Bigler et al, 2005; Yeh et al, 2005a; Moreno et al, 
2006). Larger and well-designed studies are needed to address the role of DNA 
repair polymorphisms and ageing in CRC risk. 
 74
Due to the close link with DNA repair, we have also tested the hypothesis whether 
SNPs in genes encoding some essential cell cycle control enzymes may influence 
the risk of CRC. The data analysis showed that none of the polymorphisms included 
in the present study was independently associated with the risk modulation of CRC, 
even after stratification for cancer site. However, when polymorphisms were 
analysed in binary combinations, individuals carrying at least two variant alleles for 
both TP53 PIN3 and TP53 Arg72Pro exhibited significantly increased risk of colon 
cancer. These results are in agreement with observations from previous studies: 
none of the analyzed cell cycle polymorphism has been unambiguously associated 
with CRC risk so far (Bai and Zhu, 2006; Knudsen et al, 2006). Several studies 
associated TP53 and CCND1 polymorphisms to different kind of cancers (including 
CRC). However, in the case of CCND1, associations with cancer susceptibility have 
been observed for both wildtype and variant alleles in different studies. The majority 
of studies link the CCND1 870A allele to increased cancer risk and poor disease 
outcome. On the other hand, other studies have associated the 870G allele with an 
increased cancer risk, and others have not reported any significant association with 
any allele of the G/A870 polymorphism (Grieu et al., 2003; Le Marchand et al., 
2003; Hong et al., 2005b; Jiang et al., 2006; Probs-Hensch et al., 2006; 
Schernhammer et al., 2006). A similar controversial situation can be described for 
TP53 gene polymorphisms. Functionally significant changes have been reported for 
the different genotypes in the most frequently investigated polymorphism of TP53 
gene (Arg72Pro). In some studies, the variant allele has been clearly associated with 
the age of onset of cancer and its prognosis. However, whether these variants are 
associated with an altered cancer risk is not currently clear at present (Olschwang et 
al, 1991; Kawajiri et al, 1993, Sjalander et al, 1995;Gemignani et al, 2004; Koushik 
et al, 2006). Due to multiple variants in this pathway, modulating effect of these 
SNPs would require additional, complex analyses with simultaneous addressing 
functional aspects. As a first step, analyses of haplotypes would represent much 
more powerful approach than single polymorphism investigations. 
 
This present PhD work is a part of a wider project in collaboration with other Czech 
and European Research Institute. The aim of the project is to assess the possible 
associations of numerous SNPs of genes in several different regulatory pathways 
with CRC risk. In particular, the screening of polymorphisms of genes involved in 
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metabolism of the xenobiotics, of polymorphisms in bilirubin genes or insulin-like 
growth factors are at present almost completed. The size of initial cohort of cases 
and controls from the Czech Republic is also currently increasing, since the 
sampling is still ongoing. The possibility to reach a cohort of more than 1000 cases 
and 1000 controls is desirable, in order to perform more complex investigations, 
with an adequate statistical power, even when the frequency of alleles is relatively 
low. Future studies have also to take into consideration the role of haplotypes, which 
may correlate with a disease, while single SNPs may not. 
The complex etiology of CRC and observed high incidence in Czech Republic 
stresses an importance of a systematic approach by combining epidemiological and 
molecular biological methods on large cohorts, to understand critical pathways in 
colorectal tumorigenesis. Yet, several other factors, contributing to CRC, such as 
microbial flora, inflammatory processes, stool composition etc., have to be 
simultaneously addressed.  
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6. Conclusions 
 
The major outcomes of the present PhD thesis may be briefly summarized as 
follows: 
• None of the DNA repair and cell cycle genetic polymorphisms included in this 
study was strongly associated with the risk modulation of CRC. Individuals with 
homozygous variant genotype in APE1 Asn148Glu polymorphism (BER pathway) 
were at a marginally increased risk of sporadic CRC. Above association was 
particularly pronounced in patients with colon cancer.  
• Individuals simultaneously homozygous for variant alleles of the APE1 
Asn148Glu and hOGG1 Ser326Cys polymorphisms were at significantly 
increased risk of CRC. This association was particularly pronounced in colon 
cancer patients and is indicative of multiplicative gene-gene interactions. The 
interaction between genes involved in BER is probably suggestive of a modulating 
role for inflammatory processes/oxidative stress in colon cancer. A significant 
association was also found with increased risk of colon cancer, in individuals 
carrying at least two variant alleles for both TP53 PIN3 and TP53 Arg72Pro 
polymorphism. 
• A significant interaction was revealed between smoking habit and hOGG1 
Ser326Cys polymorphism. The smokers carrying 326Cys/Cys genotype showed 
an increased risk of CRC. Age also seems to be a relevant factor affecting the 
association between APE1 Asn148Glu and an increased CRC risk, as the effect of 
above polymorphism was most pronounced in older individuals. XPG Asn1104His 
polymorphism exhibited an association with rectal cancer risk in the group of 
oldest individuals included in the study.  
CRC is a multifactorial disease which is the result of complex interactions between 
the individual genetic background and the external/internal environmental factors 
during the lifetime. The present results show a possible subtle effect of particular 
polymorphisms of DNA repair and cell cycle genes in modulating the CRC risk, 
which may be visible and supported by sufficient statistical power only on large 
cohorts of individuals. A role of SNPs in modifying the individual susceptibility to 
cancer may be more pronounced in specific tumor sites, and in concomitance with 
other polymorphisms and lifestyle factors, as well as age.  
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